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Breast cancer is a prevalent and harmful disease that is divided into subtypes based on 
tumour characteristics. The main subtype is oestrogen receptor positive (ER+), accounting 
for approximately 80% of all breast carcinomas. ER+ breast cancer presents with 
overexpression of the oestrogen receptor (ER) and is commonly treated with hormone 
therapies that block the ER from responding to oestrogen stimulus, theoretically blocking 
growth of the cancer. However, in many cases, this treatment is unsuccessful and the 
mechanisms behind this resistance remain elusive. Genetic variation in a transcriptional hub 
around the ER gene (ESR1) at 6q25.1, including three upstream genes (ARMT1, CCDC170 
and RMND1) has been correlated with increased genetic susceptibility. Therefore, 
characterisation of the gene expression at this region is important for future breast cancer 
therapies. 
SNP variants at the 6q25.1 region have been studied through genome wide association 
studies and have been associated with increased breast cancer susceptibility. The SNP 
rs77275268 within this hub is present in the human genome as either a cytosine (C) to 
thymine (T) variant within a CpG island of a known CTCF binding region. This SNP could 
affect the methylation status of this site potentially altering CTCF binding in this region. 
CTCF proteins are transcriptional regulators that bind to specific sites of the DNA and have 
been found to be affected by DNA methylation. CTCF can play a role in 3D chromatin 
structure and therefore altered binding of the protein can influence the expression of genes 
such as those in the ESR1 transcriptional hub. This project therefore aimed to elucidate the 
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expression of the genes at the transcriptional hub with the rs77275268 SNP C and T 
variants.  
Expression and correlation of these genes at 6q25.1 (ESR1, CCDC170, ARMT1 and 
RMND1) in relation to the T variant of the rs77275268 SNP was analysed using 
quantitative real-time PCR (qPCR). These results showed co-expression of ESR1 and 
CCDC170 and also RMND1 and ARMT1 supporting the hypothesis that CTCF binding 
could be altered at this genomic region. Chromatin immunoprecipitation (ChIP) was then 
utilised to determine potential changes in binding at the SNP dependent on the variant. This 
was limited by the fact that only one biological replicate was generated and therefore initial 
results produced are not conclusive, however suggest a change in CTCF binding dependent 
on the SNP variant present.  
This project also sought to produce an alternative ER+ breast cancer cell line containing the 
rs77275268 SNP T variant for further CTCF investigation through CRISPR editing. 
However, these attempts were unsuccessful with the rate of homology directed repair to 
insert the specific mutation occurring at a very low rate.  
In summary, this study demonstrated that the rs77275268 SNP T variant changes how the 
genes at the transcriptional hub 6q25.1 are co-expressed. Preliminary investigation suggests 
that the altered expression could be influenced by changes in CTCF binding resulting in a 
change in chromatin looping. Further attempts to create a SNP edited ER+ breast cancer 
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1 Introduction  
1.1 Breast cancer  
Cancer is a highly prevalent and ancient disease that can be traced back to the age of the 
dinosaurs over 65 million years ago (Rehemtulla, 2010). This disease is the second leading 
cause of mortality worldwide with a generally increasing prevalence in most western 
countries. This disease is characterised by the accumulation of multiple mutations within a 
cell that change vital genes and their typical functions (Loeb et al., 2003). As a result, the 
cell cycle is affected leading to abnormal and uncontrolled proliferation (Otto and Sicinski, 
2017).   
Breast cancer is one of the most common forms of this disease and is pervasive with almost 
1.7 million cases worldwide in 2012 (Suter and Marcum, 2007). Not only is breast cancer 
found throughout the world, it also accounts for the highest number of cancer related 
mortalities in females (Suter and Marcum, 2007). Breast cancer involves the uncontrolled 
division of the breast cells, resulting in tumours (Williams and Lin, 2013). These tumours 
can become malignant and metastasise to different areas of the body, infecting multiple 
organs (Hon et al., 2016). Breast cancer is split into two main sub types based on the 
characteristics of the tumours found in the breast tissue; oestrogen receptor positive (ER+) 
and oestrogen receptor negative (ER-) (Williams and Lin, 2013). ER- breast cancer is 
classified by tumours that do not present with an excess of oestrogen receptor expression 
(Hon et al., 2016). This form of breast cancer is much less common than ER+, which 
accounts for approximately 80% of all breast cancers worldwide (Shan et al., 2012).  
ER+ breast cancers present with a higher number of oestrogen receptors in each cell 
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relative to that found in non-cancerous tissue and ER- tumours (Shan et al., 2012). This 
increase in the amount of receptors means that the naturally produced hormone oestrogen 
binds to the excess receptors, resulting in increased oestrogenic signaling and cell 
proliferation (Thomas and Gustafsson, 2011). For this reason, patients with this form of 
breast cancer are commonly prescribed hormone treatments, such as tamoxifen, that act by 
competitively blocking the oestrogen receptors so that oestrogen cannot bind (Stadler et al., 
2010). Without the oestrogen hormone stimulus the cells lose the upregulation of growth 
and proliferation, which can slow cancer growth (Thomas and Gustafsson, 2011). However, 
it has been found that resistance to this hormone treatment is relatively common, with many 
patients enduring unpleasant side effects without significant or long term benefit (Dunbier 
et al., 2011).  
1.2 Genome wide association study  
Within this ER+ breast cancer subtype, there have been a number of single nucleotide 
polymorphisms (SNPs) linked with increased genetic susceptibility to breast cancer (Stacey 
et al., 2010). SNPs are mutations in the DNA characterised by a single base pair change and 
have been extensively studied in ER+  breast cancer through genome wide association 
studies (GWAS) (Shan et al., 2012). GWAS are a potentially powerful way of identifying 
susceptibility loci in cancers and have been employed for association studies to identify 
common SNPs associated with cancer  (Easton and Eeles, 2008). This method compares 
allele frequencies between populations with and without the disease, to determine which 
SNPs occur at different frequencies between the two populations (Stadler et al., 2010).  In a 
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GWAS performed by Stacey et al., (2010), the SNP rs77275268, with two genetic variants,  
either a cytosine (C) or a thymine (T), was found in a CpG island close to ESR1 (Stacey et 
al., 2010). The association of SNP rs77275268 with increased genetic susceptibility to ER+ 
breast cancer is the motivation for this project as ER+ breast cancer is the most dominant 
breast cancer subtype (Dunbier et al., 2011). This project will focus on the effects of the C 
and T variants in the non-coding SNP found on chromosome 6 at position q25.1; 
rs77275268. This SNP is thought to be important in linking the expression of three key 
genes upstream of the oestrogen receptor gene (ESR1) (Dunbier et al., 2011). Correlation of 
the expression of these ORFs has been hypothesised to have an association with increased 
breast cancer risk and resistance to hormone treatment (Dunbier et al., 2011). The location 
of this SNP, in a CpG island, had led to the postulation that the SNP could be causally 
linked to ER+ breast cancer and increased genetic susceptibility to the disease (Stacey et 
al., 2010).  The position of these genes in the 6q25.1 region and the relative position of the 
SNP on chromosome 6 can be seen in Figure 1.1. 
 
 
Figure 1.1 Linear model of the genes on chromosome 6 at position q25.1.  
The relative locations of RMND1, ARMT1, CCDC170 and ESR1 with the relevant SNP rs77275268. 
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1.3 CpG islands and gene expression 
Spread out, human DNA within each cell is approximately 2 meters long. However tight, 
and precise packaging of the chromatin allows it to fit within a nucleus of approximately 6 
#m diameter (Alberts et al., 2002). To achieve this tight packaging, the double stranded 
DNA helix is wrapped around histone proteins forming a nucleosome (Khorasanizadeh, 
2004). Multiple nucleosomes are then folded together in cell-specific ways to form the 
chromatin which in turn forms the chromosomes found in the nucleus of the cell as shown 
in Figure 1.2. (Alberts et al., 2002). Different modifications at each level of this DNA 














Figure 1.2. Schematic of how DNA is packaged into chromatin. 
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The structure of chromatin is very important as it effects transcription and expression (Zuin 
et al., 2014). Chromatin can influence gene expression through its 3D conformation, the 
affects of which are dependent on the spatial organisation (Rowley and Corces, 2018). This 
organisation can be split into multiple levels based on the size of the component (Li and 
Reinberg, 2011). Megabase-scale compartments refer to euchromatin and heterochromatin, 
sub-megabase compartment are topologically associated domains and the tens of kilobases 
compartment have smaller loop structures that connect cis-regulatory elements (Aitken et 
al., 2018).  
Histones that help to form the nucleosome have tails that can be modified generally via 
acetylation or methylation (Sanli et al., 2011). An acetylated histone modification is 
commonly associated with active or open euchromatin where genes are actively 
transcribed, while methylation is associated with repressed heterochromatin or closed 
chromatin where genes are not transcribed (Bannister and Kouzarides, 2011).  
DNA methylation is a heritable, epigenetic modification that aids in controlling gene 
transcription and expression (Klose and Bird, 2006). Methylation is a key determining 
factor in the accessibility of chromatin as differential methylation affects chromatin 
packing which determines how proteins are able to bind DNA (Razin, 1998). Generally, 
methylation is associated with a repressive chromatin state, preventing the binding of 
transcription factors resulting in the inhibition of transcription in that area (Wallace and 
Felsenfeld, 2007).  
CpG islands are areas of the DNA that contain relatively high proportions of C and guanine 
(G) bases (Deaton and Bird, 2011). When a C is immediately adjacent to a G, it can be 
methylated on the 5 position of the C ring and therefore, CpG islands are usually associated 
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with higher levels of methylation compared to the genome in general (Jang et al., 2017). 
Adenine (A) and T bases cannot be methylated and therefore the presence of a T, which 
cannot be methylated, rather than a C, which can be methylated, as may occur at 
rs77275268, could alter gene expression. Protein binding is known to be affected by the 
methylation status of the DNA, therefore methylation of CpG islands may affect gene 
expression through the recruitment or inhibition of proteins that influence transcription 
(Tate and Bird, 1993).  
1.4 CTCF and cohesin  
CCCTC-binding factor (CTCF) is an 11 zinc finger transcription factor involved in 
transcriptional activation and repression (Klenova et al., 1993). CTCF binds to the 
consensus sequence shown in Figure 1.3., however this is variable as the protein has been 
shown to bind to a variety of differing sequences using varying combinations of the 11 zinc 









Figure 1.3. Consensus sequence of the DNA binding motif for CTCF. 




CTCF can recruit many co-factors to binding sites and has been shown to interact with 
other DNA-binding proteins and transcription factors as well as proteins that interact with 
histones and even histones directly (Wallace and Felsenfeld, 2007). Through this 
assortment of interactions, CTCF can have many effects on transcription through a number 
of different mechanisms.  
CTCF has been identified as the only major insulator binding protein (Cuddapah et al., 
2009). Insulators act on DNA by inhibiting interactions between neighbouring regions of 
the genome which might otherwise lead to inappropriate activation or repression of the 
gene (Yang and Corces, 2012). This is achieved by proteins that bind these DNA elements 
and mediate this activity, such as CTCF (Felsenfeld et al., 2004). Poly(ADP)ribosylation of 
CTCF is a common modification of the protein, inhibition of which has been shown to 
impair its ability to function in this insulator role (Gaszner and Felsenfeld, 2006).  
As well as its insulator interactions, CTCF binding sites are often found between 
complementary histone acetylation and methylation, implicating the protein in the 
separation of repressed and active regions of the genome (Wallace and Felsenfeld, 2007).  
CTCF also has a role in the 3D structuring of chromatin in the genome (Hansen et al., 
2017). Long range interactions between distant pairs of sites that bind CTCF can form 
chromatin loops and it is thought that CTCF dimerisation may stabilise these interactions 
(Phillips and Corces, 2009). Chromatin looping may also be formed through CTCF 
interactions with other target proteins at distant sites in the chromosomes and therefore may 
not be limited to CTCF dimerisation or specificity (Holwerda and de Laat, 2013).  
One such protein that CTCF has been found to interact with at this level is cohesin. CTCF 
and cohesin have been shown to work co-operatively to determine chromatin structure 
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through the formation of chromatin loops (Figure 1.4.) (Busslinger et al., 2017) (Chien et 
al., 2011). CTCF provides ‘contact points’ for long range, cis-interactions for modifying 
chromatin structure, these structures are stabilised by cohesin (Sofueva et al., 2013). 
However, despite this structural influence, the mechanism underlying cohesin recruitment 
to CTCF sites and how it influences gene expression is still not completely understood 








Through topology based models, it has been found that transcriptional activation can be 
affected by the structure of the DNA favouring intra loop interactions over inter loop 
interactions (Gaszner and Felsenfeld, 2006). This occurs because when an enhancer and 
promoter are found in separate DNA loops, insulators that block enhancer activity may 
disrupt interaction between the two (Bushey et al., 2008). Therefore, CTCF may be able to 
block gene expression and transcription by binding to an insulator element in the DNA 
between two loops containing inter-connected genetic elements, required for expression 
(Merkenschlager and Odom, 2013). However, the effect CTCF has on large scale 
Figure 1.4. DNA looping with CTCF and cohesin.  
Example of potential chromatin loop structure formed by CTCF and cohesin proteins. 
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chromatin interactions may in some cases facilitate gene expression rather than inhibiting it 
(Gaszner and Felsenfeld, 2006).  
CTCF is predicted to have a role in the effect of the SNP of interest in breast cancer. Not 
only does the SNP of interest in this project occur in a CpG island, but that CpG island is 
within a known binding site for the chromatin modelling protein CTCF (Stacey et al., 
2010). CTCF DNA binding sites commonly contain CpG islands, the core consensus 
sequence of this binding motif is shown in Figure 1.3. (Davis and Chen, 2013). This means 
that DNA recognition and binding can be blocked by the methylation of CpG islands at the 
transcription factor binding site (Rodgers and McVey, 2016).This leads to the hypothesis 
that CTCF preferentially binds to non-methylated CpG islands and the methylation status 
of these islands could act as a mechanism for the regulation of gene expression (Davis and 
Chen, 2013). 
1.5 CRISPR-Cas9 
One way to study the effects of specific SNPs is to generate genome edited cell lines with 
specific SNP variants. These cell lines can then be compared to matched cell lines that do 
not have the variant to identify changes that are a result of the SNP in question (Hon et al., 
2016). A commonly used methodology for achieving this is to employ the CRISPR-Cas9 
system, specifically utilising the homology-directed repair process that allow for precision 
insertion of a desired sequence (Mao et al., 2016). CRISPR-Cas9 technology was modified 
from the adaptive immune system of bacteria to detect and target specific sequences for 
cleavage (Doudna and Charpentier, 2014). This system of cleavage has since been modified 
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to allow for the insertion and/or deletion of specific bases, allowing for the introduction of 
point mutations (Doudna and Charpentier, 2014).  
CRISPR/Cas9 gene editing requires two main components to achieve a double stranded 
break in DNA that can be exploited by for subsequent genetic editing (Yumlu et al., 2017). 
Namely, the cas9 nuclease protein that performs the DNA ‘cutting’, and a single guide 
RNA that leads the cas9 protein to the specific region of DNA for intended editing (Jiang 
and Doudna, 2017). The gene editing process follows the production of double stranded 
breaks whereby natural DNA repair pathways result in deletion, replacement or insertion of 
sequences (Shen et al., 2017). To be able to maintain genomic integrity and stability, cells 
have developed two main pathways to remedy DNA lesions generated both spontaneously 
and as a result of exogenous damage (Iliakis et al., 2004). The naturally occurring DNA 
repair pathways can be manipulated to achieve the specific type of gene editing desired, 
usually either via non-homologous end joining (NHEJ) or homology directed repair (HDR) 


















NHEJ essentially just involves processing of the broken ends of the DNA followed by 
subsequent joining (Davis and Chen, 2013). However, this crude yet simple approach is 
frequently associated with small base pair insertions and deletions (Rodgers and McVey, 
2016). NHEJ is regularly used in CRISPR experiments involving gene knock-outs. This is 
because NHEJ often results in frame shift mutations and premature stop codons which can 
lead to the cell not processing the part of DNA containing the gene intended for knock-out 
(Sharpe and Cooper, 2017). While this method is useful due to its greater simplicity and 
Figure 1.4. Schematic of DNA repair after CRISPR editing. 
Parallel lines represent double stranded DNA.  
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efficiency compared to HDR, it cannot be robustly utilised for generating precise genetic 
modifications, such as a SNP (Ryu et al., 2019).  
To achieve specific point mutations in the DNA rather than simply disruption of the 
sequence, manipulation of the HDR pathway for the double stranded breaks is required 
(Yumlu et al., 2017). This process requires a ‘donor DNA’ molecule to act as a repair 
template from which the broken strands of DNA can be repaired (Davis and Chen, 2013). 
Normally in cells, the DNA molecule that would be utilised for this repair is the sister 
chromatid within the cell, however manipulation of this can be achieved by the addition of 
an artificial DNA template that mimics the sister chromatid (Tang et al., 2019). This 
exogenous piece of DNA has to contain homologous sequence either side of the double 
stranded break, as well flanking the intended mutant base to act as the point mutation (Tang 
et al., 2019). However, although precise, the efficiency of HDR is limited by the alternative 
NEHJ pathway as the two compete to repair the broken DNA (Maruyama et al., 2015). As 
well as this competition, HDR only occurs in the S or G2 phases of the cell cycle, unlike 
NHEJ which can occur at any point in the cell cycle (Platt et al., 2014). Due to to the low 
frequency of HDR within cells, the efficiency of insertional mutagenesis via utilisation and 
manipulation of this pathway is predicted to be only 0.5-2% approximately (Maruyama et 
al., 2015).  
Although the use of this programmable nuclease system is an effective method for studying 
particular mutations in malignant tumours, off target effects, which can introduce unwanted 
mutations and hinder results (Platt et al., 2014), (Veeraraghavan et al., 2014). 
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1.6 Genetic correlation of C6orfs 
Following on from Stacey et al., (2010), Dunbier et al., (2011), investigated the correlation 
of the expression of several ORFs and the ESR1 locus in the 6q25.1 region (Dunbier et al., 
2011). Following testing of gene expression over time in breast cancer cells, a novel 
correlation between the expression of the C6ORFs and ESR1 was discovered (Dunbier et 
al., 2011). It was found that expression of three of the C6ORFs in particular were highly 
correlated with ESR1: C6ORF97 (now re-named CCDC170), C6ORF211 (now re-named 
ARMT1) and C6ORF96 (now re-named RMND1), in ER+ cell lines and breast tumours 
(Dunbier et al., 2011). Investigation into these C6ORFs has not revealed any conclusive 
functions - although many functions have been postulated, they are still poorly understood. 
The rs77275268 SNP is found in the same region as these genes and has been associated 
with an increased genetic susceptibility to breast cancer and is linked to tamoxifen 
treatment resistance (Stacey et al., 2010).  
This novel correlation between ESR1 expression and the expression of the three upstream 
genes in the 6q25.1 region suggested that further analyses of how these genes are correlated 
and the down-stream cellular effects of this correlation, could produce important insight 
into  breast cancer risk and treatment resistance (Dunbier et al., 2011). This project will 
focus on the SNP rs77275268 and whether this change is associated with the observed 
correlation between the RMND1, ARMT1, CCDC170 and ESR1 and if so, the mechanisms 
behind this. Understanding the mechanisms behind the increased genetic susceptibility 
associated with this SNP could inform future therapeutic targets and allow for more 
accurate treatment programs. Therefore, the mechanisms behind the increased breast cancer 
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susceptibility associated with this genetic variant warrants further investigation which will 
be the focus for this thesis.  
1.7 Aims  
The overall aim of this project was to investigate the effect of the rs77275268 SNP on 
regulation of gene expression at the transcriptional hub on 6q25.1 in ER+ breast cancer 
cells. It was predicted that the SNP would result in alternate chromatin looping due to the 
change in methylation in a CTCF binding site. The predicted change in methylation at this 
SNP site was postulated to affect how the CTCF protein binds and/or recruits other proteins 
that control gene transcription. This change may be linked to the correlation of the RMND1, 
ARMT1 and CCDC170 genes with ESR1, changing the characteristics of the cells leading to 
the observed increased susceptibility of breast cancer. To investigate the effect of the SNP 
on the C6ORFs and ESR1, gene expression analysis was performed using RT-qPCR. 
Following this, the predicted change in CTCF protein binding was investigated. This was 
done firstly in the previously edited MCF-7 derived clones, PXY62 and PX459-6 (C) and 
DSB10, DSB19 and D10A5 (T). Subsequently, CRISPR/cas9 was used to attempt to 
generate clones containing the SNP of interest derived from T-47D cells for further 







2 Materials and Methods  
2.1 Materials  
2.1.1 Reagents  
1Kb Universal DNA ladder – Kapa Biosystems, USA   
Agar Bacteriology grade – AppliChem GmbH, Germany 
Agarose low EEO – AppliChem GmbH, Germany 
Ampicillin – Roche Applied Science, Germany 
BbsI – Thermo Fisher Scientific, USA 
Charcoal stripped foetal bovine serum (DCC) – Invitrogen, USA  
D10A+3-1 – Integrated DNA Technologies, Inc., USA   
D10A+3-2 – Integrated DNA Technologies, Inc., USA   
Ethanol (EtOH) – Lab Supplies, New Zealand  
Ethidium bromide solution – Invitrogen, USA  
Foetal bovine serum (FBS) – Invitrogen, USA  
Hoechst 33342 Solution – Thermo Fisher Scientific, USA   
Hyclone TM Trypan Blue Stain – Thermo Fisher Scientific, USA   
HRM rs77275268 5’ – Integrated DNA Technologies, Inc., USA 
HRM rs77275268 3’ – Integrated DNA Technologies, Inc., USA 
Insulin (Actrapid® Penfill® 100 IU/mL) – Novo Nordsik®, Denmark 
Isopropanol – Lab Supply, NZ   
KpnID10A+3-1 – Integrated DNA Technologies, Inc., USA   
KpnID10A+3-2 – Integrated DNA Technologies, Inc., USA   
	 16	
Luminaris Colour HRM qPCR Master Mix – Thermo Fisher Scientific, New Zealand 
Michigan Cancer Foundation – 7 (MCF-7) cell line – American Type Culture Collection, 
USA   
Milli-Q – EMD Millipore, USA   
SNP Seq 5’ – Integrated DNA Technologies, Inc., USA  
SNP Seq 3’ – Integrated DNA Technologies, Inc., USA  
Nocozaole – Sigma Aldrich, USA   
Paraformaldehyde, Powder, 95% – Sigma Aldrich, USA   
Penicillin Streptomycin (10,000 U/mL) – Life Technologies, USA 
Phosphate Buffered Saline – Thermo Fisher Scientific, USA   
Plasmid PTE4254: pcDNA3.3-TOPO – Addgene, USA 
Plasmid PX458: pSpCas9(BB)-2A-GFP – Addgene, USA 
Platinum Taq DNA polymerase – Life Technologies, USA   
PrimeScriptTM RT reagent Kit (Perfect Real Time) – Takara Bio Inc., Japan   
Primetime standard qPCR assay ESR1 Hs.PT.49a.746988 – Integrated DNA Technologies, 
Inc., USA   
Primetime standard qPCR assay ARMT1 Hs.PT.49a.3485748 – Integrated 
DNA Technologies, Inc., USA   
Primetime standard qPCR assay CCDC170 Hs.PT.49a.509482 – Integrated DNA 
Technologies, Inc., USA   
Primetime standard qPCR assay CCDC170 (exons 2-3) Hs.PT.58.39815203 – Integrated 
DNA Technologies, Inc., USA  
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Primetime standard qPCR assay RMND1 Hs.PT.49a.4325065 – Integrated DNA 
Technologies, Inc., USA   
Primetime standard qPCR assay FKBP15 Hs.PT.49a.2552313 – Integrated DNA 
Technologies, Inc., USA   
Primetime standard qPCR assay PUM1 Hs.PT.56a.1997572 – Integrated DNA 
Technologies, Inc., USA   
PureLinkTM RNase A – Thermo Fisher Scientific, USA  
Quick RNA miniprep kit – Zymo Research, USA  
RMPI 1640 [+] L-Glutamine media – Sigma Aldrich, USA     
Sodium Acetate – Scharlau, Spain  
Sodium bicarbonate – Scharlau, Spain 
Sodium dodecyl sulphate (SDS) – Asia Pacific Specialty Chemicals Limited, Australia   
SNP seq 3’ – Integrated DNA Technologies, Inc., USA  
SNP seq 5’ – Integrated DNA Technologies, Inc., USA   
Superscript® III Reverse Transcriptase – Life Technologies, USA 
T-47D cell line – American Type Culture Collection, USA 
TaqMan® Gene Expression Master Mix – Applied Biosystems, USA 
Thermal seal, Real-time PCR Optical plastic sheet – Interlab Ltd, New Zealand   
TransIt-Brca Transfection Reagent – Mirus® Bio, USA 
Trypsin/EDTA – Invitrogen, USA  
U6 primer – Integrated DNA Technologies, Inc., USA   
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2.1.2 Equipment  
1.7 mL microfuge tube – SorensonTM BioScience, Inc., USA  
15 mL and 50 mL tubes – Greiner Bio-one, Switzerland  
100 mm Corning® tissue-culture treated culture dishes – Sigma Aldrich, USA 
25cm2 and 75cm2 Cellstar cell culture flasks – Greiner Bio-one, Switzerland  
384-well optical plate – Applied Biosystems, USA  
6-well, 24-well, and 96-well Cellstar cell culture plates – Greiner Bio-one, Switzerland   
ABI Prism 7900 HT – Applied Biosystems, USA  
C1000TM ThermoCycler – Bio-rad, USA  
Corning® 1L Filter System – Corning, USA  
CytationTM 5 Cell Imaging Multi Mode Reader – BioTek, USA  
HeracellTM 150i CO2 Incubator – Thermo Fisher Scientific, USA 
IEC Centra-4 x Centrifuge – International Equipment Company, USA  
LightCycler® 480 Instrument II - Roche Applied Science, New Zealand 
LightCycler® 480 multiwell plate 96, white – Roche Applied Science, New Zealand 
Molecular Imager® Gel DocTM XR+  
Nanodrop 1000 – Nanodrop Technologies, USA  
2.1.3 Software 
4Peaks – Nucleobytes USA 
Cytell Cell Imaging System – GE Healthcare Life Sciences, United Kingdom   
ImageJ – National Institutes of Health, USA  
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Image LabTM 4.0 – BioRad, USA  
LightCycler® 480 Software Version 1.5 – Roche, NZ 
Microsoft Excel – Microsoft, USA  
Prism 6.0 – GraphPad Software, Inc., USA  



















2.2.1 Cell culture 
The Michigan Cancer Foundation -7 (MCF-7) and T-47D human breast cancer cell lines 
used were obtained from the American Type Culture Collection (ATCC). 
2.2.1.1 Cell Maintenance  
MCF-7 cells were grown and kept in 75 cm2 CellStar cell culture flasks with RPMI 1640 
[+] L-Glutamine media, which will be now be referred to as ‘MCF-7 full media’, 
supplemented with 10 % foetal bovine serum (FBS). T-47D cells were kept in the same 
conditions with 0.28 % insulin added to MCF-7 full media to create ‘T-47D full media’. 
The cells were incubated at 37 ℃ in 5 % CO2 in a humidified HeracellTM 150i CO2 
incubator.  
Cells were passaged once 80 % confluency was reached in the flask. All reagents used were 
pre-warmed for at least 20 minutes in the 37 ℃	water bath. The media was removed and 
replaced with 4 mL phosphate-buffered saline (PBS) which was subsequently removed and 
replaced with 4 mL 0.05 % trypsin/PBS. The cells with trypsin were incubated at 37 ℃ for 
4 minutes and checked for detachment from the flask. Five mL of full media was added to 
the flask to dilute and quench the trypsin and ensure complete detachment. Cells were 
mixed and transferred to a 15 mL Falcon tube. The suspension in the 15 mL Falcon tube 
was centrifuged at 70 x g for 5 minutes to create a cell pellet. The resulting supernatant was 
removed and the cell pellet was resuspended in 1 mL full media. Cells were seeded at 1:10 
for MCF-7 cells and 1:5 for T-47D cells into a new 75 cm2 CellStar cell culture flask with 
10 mL of full media. This flask was then returned to the incubator.   
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2.2.1.2 Thawing frozen cells  
Cells were kept frozen in a liquid nitrogen Dewar until needed. Cells were removed from 
liquid nitrogen and thawed in the 37 ℃ water bath. Once thawed, the 1 mL suspension was 
transferred to a 15 mL falcon tube. One mL of pre-warmed media was used to wash out any 
remaining cells and transferred to the 15 mL falcon tube. This mixture was made up to 5 
mL with full media and centrifuged for 5 minutes at 80 x g. The supernatant was aspirated 
and the cell pellet resuspended in 1 mL complete media. This was added to a 25 cm2 
CellStar cell culture flask with pre-added full media (5 mL). Cells were kept in a 
humidified incubator set at 37 ℃ and 5 % CO2. Media was changed after 24 hours to ensure 
removal of any residual DMSO used to freeze down the cells. Cells were split at least twice 
after thawing, before use in experiments.  
2.2.2 Optimisation of Seeding Density 
2.2.2.1 Cell seeding 
Cells intended to be seeded onto plates were passaged as in Section 2.2.1.1 until the point 
of 1 mL resuspension of the cell pellet. 10 µL of this 1 mL resuspension was transferred 
into a 1.7 mL eppendorf and 10 µL of trypan blue was added and mixed well. The Luna II 
automated cell counter was used to count the number of cells so that the volume of the 1ml 
suspension needed for seeding of a specific number could be calculated. Six well Costar ® 
plates were seeded in duplicate with 150,000, 200,000 or 250,000 cells per well in 2 mL of 
oestrogen deprived (DCC) media that did not contain oestrogen and the plate returned to 
the incubator. 24 hours after seeding, the media was replaced with 1 nmol.L-1 of  β-
Estradiol (E2) added to 3 of the 6 wells. 
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2.2.2.2 RNA extraction  
RNA from 1 x 6 well plate for each of the 3 investigated seeding densities was extracted at 
both 24 and 72 hours after seeding. RNA was extracted using the Zymo quick-RNA 
MiniPrep kit and the provided protocol was followed. RNA was eluted in 35µL of 
DNase/RNase free water and kept on ice for quantification.  
2.2.2.3 RNA Quantification  
The concentrations obtained in the extracted RNA samples were quantified using the 
NanoDrop 1000 spectrometer. DNase/RNase free water was used to reset the machine to 
zero and once quantified, samples were stored at –80 ℃ until further use.  
2.2.2.4 Cytation  
The cells of interest were fixed and stained by adding 1 mL fix and stain solution 
containing 0.5 % paraformaldehyde, 0.15 % saponin and 2	µg/mL Hoescht 33342 was 
added to each well to create a 1:1 ratio of fix stain to full media. The plate was wrapped in 
tin foil and shaken for 20-30 minutes. The cells were then imaged using the UV filter on the 
Cytell Cell Imaging System followed by analysis using the Cytell Cycle Kit to count the 
number of nuclei.  
2.2.3 Gene Expression Analysis of ESR1, ARMT1, RMND1 AND CCDC170 
2.2.3.1 Cell Seeding  
Cells were seeded into 8 x 6 well plates as per Section 2.2.2.1, at 200,000 cells per well. 24 
hours post seeding E2 was added to half of the plates at 1 nmol.L-1 concentration. Cells 
were seeded in 2 x 6 well plates for each time point with one of the two plates deprived of 
E2 (DCC media only) and the other plate had E2 added at ‘0 hours’. On each plate, 3 of the 
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wells were seeded with the control cell line and the other 3 wells were seeded with cells 
from the edited cell line.   
2.2.3.2 RNA extractions 
For optimisation of seeding densities, RNA was collected at 24 and 48 hours post seeding. 
For all other experiments, RNA was collected at 0, 8. 24 and 48 hours or at 0, 3, 6 and 12 
hours. This was done using the Zymo quick-RNA MiniPrep kit and provided protocol was 
followed. RNA collected was eluted in 35 µL of DNase/Rnase free water and kept on ice.  
2.2.3.3 RNA Quantification  
RNA quantification was performed as described in 2.2.2.3. 
2.2.3.4 Sample cDNA conversion 
Complementary DNA (cDNA) synthesis from RNA samples extracted were made from 3.5 
µL of master mix shown in the Table 2.1 and 6.5 µL of RNA. The 5 µL of RNA added had 
a total amount of 500 ng for each reaction.  
2.2.3.5 Standard cDNA conversion  
cDNA for the qPCR standards were made from RNA extracted from MCF-7 cells 48 hours 
post E2 addition as previously described in Section 2.2.3.2. 2000 ng of RNA was made up 
in 5 µL which was then added to 5 µL of master mix as shown in Table 2.1. below.  
2.2.3.6 No reverse transcriptase control  
No reverse transcriptase controls were created by replacing the Prime Script RT enzyme 
Mix I with 0.5 µL of MQH2O to ensure the volume remained 5 µL as in Section 2.2.3.4. 
This was added to one sample from each time point with the highest concentration of RNA.  
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Table 2.1. Master Mix Components for cDNA Synthesis. 
Reagent  Sample (%L) Standard (%L) No RT control (%L) 
5x PrimeScript Buffer 2 2 2 
PrimeScript RT Enzyme 
Mix I 
0.5  0.5 - 
Oligo dT Primer (50 µM) 0.5 (25 pmol) 0.5 (25 pmol) 0.5 (25 pmol) 
Random 6 mers (100	µM) 0.5 (50 pmol) 2 (200 pmol) 2 (50 pmol) 
RNA 6.5 (500 ng) 5 (2000 ng) 5 (500 ng) 
MQH2O - - 0.5 
Total volume  10 10 10 
2.2.3.7 PCR  
cDNA mixtures in PCR tubes were centrifuged and put into the C1000TM Thermal Cycler. 
The protocol was 15 minutes at 37 ℃, then heating to 87 ℃ for 5 seconds then 4 oC for 5 
minutes. Once this reaction was complete, samples were kept at –80 ℃ until use.  
2.2.3.8 Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) 
Sample cDNA was diluted to 4.44 ng/µL using MQH2O and 4.5 µL of this was added to 
each well in a MicroAMP ® Optical 384 well reaction plate in triplicate.  
Standard cDNA was serially diluted to create a standard curve of 150 ng, 100 ng, 20 ng, 2 
ng, and 0.2 ng. These were plated in triplicate on the MicroAMP® Optical 384 well 
reaction plate alongside the samples. No RT controls and blank controls were also plated in 
triplicate. Five µL of Taqman Gene Expression Master Mix was combined with 0.5 µL of 
PrimeTime® qPCR Assay Probes (Tables 2.3 and 2.4) and subsequently added to each well 
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along with 4.5 µL of the previously diluted cDNA. The plate was sealed using an Interlab 
Real Time PCR Thermal Seal before being centrifuged for five minutes at 500 x g. The 
ABI 7900HT sequence detection sequence programme was then used to run the cycles in 
the Table 2.2  
Table 2.2.2. Cycle Temperature and Time for qPCR. 
Stage Temperature (℃) Time 
(minute:second) 
Number of cycles 
1 50 2:00 1 
2 95 10:00 1 
3 95 0:15 40 
 60 1:00  
4 95 0:15 1 
 60 0:15  
2.2.3.9 qPCR analysis  
qPCR data was analysed using SDS 2.4 software following the Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments Guidelines. Relative RNA was 
quantified for the genes of interest (ESR1, ARMT1, RMND1 and CCDC170) after threshold 
was set automatically in the linear phase. The Quantification cycle (Cq) for each gene of 
interest was compared to the standard curve and all data was normalised using the 
geometric mean of the reference genes PUM1 and FKBP15.  
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2.2.3.10 Statistical analysis of qPCR 
Normalised, relative gene expression was analysed using PRISM 6.0 and graphed 
displaying plus/minus the standard error of the mean. Results were analysed using one-way 
ANOVAs. 
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Table 2.2.3. qPCR Genes of Interest Primer Probe Assay ID and Sequences for Cell Line qPCR. 
Gene Assay ID Probe Sequence Primer 1 Primer 2 
ESR1 HS.PT.49a.746988 5’-56-FAM/TCCCACCTT/ZEN/TCATCATTCCCACTTCG/CIABkFQ/-3’ 5’-TTCAACATTCTCCCTCCTCTTC-3’ 5’-CTATATGTGTCCAGCCACCAA-3’ 
ARMT1 HS.PT.49a.3485748 5’-56-FAM-TTTCAGCTT/ZEN/CCACGCCTTCCTCTC/CIABkFQ/-3’ 5’-TCTGTTTGCAATTCATTCCGTAA-3’ 5’-GGTTATTGATACATTGCATCGACA-3’ 
RMND1 HS.PT.49a.4325065 5’-56-FAM/AGGCCAGAT/ZEN/CTTGAGAGAGATTCCC/CIABkFQ/-3’ 5’-ATTTTCCACACCCATCACCA-3’ 5’-AACGAGGACCTAATGCATG-3’ 
CCDC170 HS.PT.49a.509482 5’-56-FAM/TCTGATGCC/ZEN/TTGTCATTCCTCTCATCTG/CIABkFQ/-3’ 5’-CTTTCAGGCCTTCATTTTCTTTGCG-3’ 5’-TTCTGACTCAACTGCGTGAC-3’ 
CCDC170 (2-3) HS.PT.58.39815203 5’-56-FAM/ACTTCGAGC/ZEN/ATTTTGAGCCACATTCC/3IABkFQ/-3’ 5’-CAGTTCTTGACAGGAGACTTCT-3’ 5’-CGGAGCAGTTAAACCACT-3’ 
 
 
Table 2.2.4. qPCR Reference Genes Primer Probe Assay ID and Sequences for Cell Line qPCR. 
Gene Assay ID Probe Sequence Primer 1 Primer 2 
FKBP15 HS.PT.49a.2552312 5’-56-FAM/AACTTCACC /ZEN/CGGCCTAACCTCCAC/CIABkFQ/-3’ 5’-TGTGACCATCAGAGCCAGA-3’ 5’-CGATTGCTTATTGTCCCTCCA-3’ 




2.2.4 Determination of the rs77275268 SNP genotype 
2.2.4.1 Genomic DNA extraction  
gDNA was extracted from MCF-7 cells and the cells from edited MCF-7 derived cell 
lines; PX549-6, PXY62, DSB10, D10A5 and DSB19 from confluent 75 cm2 cell culture 
flasks. Cells were transferred to 15 mL falcon tubes and spun at 80 x g for 5 minutes 
and the supernatant was aspirated off. Cells were lysed with 600 µL of nuclear lysis 
buffer (Appendix 7.1.) and mixed well. Three µL of 100 µg/mL RNase A was added to 
the samples and incubated for 30 minutes at 37 oC. Samples were cooled to room 
temperature and 200 µL of 10 mmol ammonium acetate was added before being chilled 
on ice for 5 minutes. Samples were mixed by inversion and then spun at 30,000 x g for 
10 minutes in a 4 oC centrifuge. Supernatant was removed and 600 µL of 75 % ethanol 
was added. Samples were spun at 30,000 x g for 10 minutes at 4 oC and the supernatant 
was removed and the resultant pellets were left to air dry overnight. This pellet was 
resuspended in 50 µL of Qiagen buffer IDTE and heated for 30 minutes at 65 oC before 
the DNA was stored at -20 oC indefinitely.  
2.2.4.2 PCR  
gDNA extracted from the 6 cell lines was amplified for further analysis following PCR 
protocols in Tables 2.5 and 2.6, using the forward primer SNPseq 









Table 2.2.5. PCR Reactions to Amplify the rs77275268 SNP Region. 
Reagent Amount ("L) 
Kapa HS ready mix 5 
Forward Primer (10 µM) 0.5 
Reverse  Primer (10 µM) 0.5 




Table 2.2.6. PCR Thermal Profile to Amplify the rs77275268 SNP Region. 
Step Temperature Duration Cycles 
Initial denaturation 95 ℃ 3 minutes 1 
Denaturation 98 ℃ 20 seconds  
Annealing 60-75 ℃ 15 seconds 15-35 
Extension 72 ℃ 15-60 seconds/kb  
Final extension 72 ℃ 1 minute/kb  
 
2.2.4.3 Gel  
Two % agarose gel was used to visualise PCR products. Gels were made by heating 
agarose powder (Hydragene) in 1 x Tris acetic acid EDTA (TAE) buffer with ethidium 
bromide (10 mg/mL). The resulting gel was placed in a gel tank with 1 x TAE buffer 
with ethidium bromide (10 mg/µL). Prior to loading, 4 µL of PCR products were mixed 
with 1 ul of 6 x DNA loading dye. Four µL of Kapa universal ladder (Kapa Biosystems) 




up to 40 minutes at 90 V. Gels were visualised and photographed under UV light with 
the GelDoc Transilluminator (BioRad) with QuantityOne software.  
2.2.4.4 DNA clean up 
PCR products were resuspended in 5 x total volume of 100 % ethanol with 0.3 M 
sodium acetate. This was transferred to a DNA spin column and collection tube to be 
centrifuged for 1 minute at 5000 x g. The supernatant was subsequently discarded and 
the DNA was cleaned by adding 200 µL of 70% ethanol followed by centrifuging at 
5,000 x g for 1 minute. Columns were centrifuged a second time at 14,000 x g for 3 
minutes to dry the column and then transferred to a new collection tube. 50 µL of 
MQH2O was added to the column and left for 5 minutes at room temperature. The 
column was finally centrifuged at 5,000 x g for 1 minute and the eluted DNA was stored 
at 4 oC.  
2.2.4.5 DNA sequencing  
 Primers for sequencing were diluted to 3.2 pM. One µL of cleaned PCR product (up to 
40 ng/µL) and 1 µL of 3.2 pmol/	µL primer (either forward or reverse) and 3 µL of 
MQH2O was added to individual strip tubes with one sample in each tube. This was sent 
to the Genetic Analysis Services (University of Otago) for Sanger sequencing. 
Sequences were analysed using 4peaks software (Version 1.7.1).  
2.2.5 Bacterial transformations and molecular cloning  
2.2.5.1 Plasmid stocks  
Addgene plasmids PX458 and PTE4254 were used for CRISPR/Cas9 genome editing. 
PX458 plasmid and plasmid TOPO31 (rs77275268 T) were obtained as a glycerol stock 
from pre-existing lab stocks. PTE4254 plasmid was obtained from Addgene as a 




2.2.5.2 Plasmid DNA extractions from bacterial cultures  
Single bacterial colonies was inoculated with 1 x LB containing 100	µg/mL	ampicillin 
and grown overnight at 37 ℃. Plasmids were subsequently extracted using the 
Machery-Nagel NucleoSpin® Plasmid Kit as per the manufacturer’s protocol. The 
plasmid DNA was eluted in 50 µL	MQH2O and the concentration was determined using 
the NanoDrop 1000 spectrometer as per 2.2.2.3.  
2.2.5.3 Molecular cloning  
Restriction enzyme digest components in Table 2.7. were added to a 1.7 mL Eppendorf 
tube and heated overnight at 37 ℃. The digestion product was checked on a 2 % 
agarose gel and purified using the DNA clean up in 2.2.4.4.  
Table 2.2.7. BbsI Restriction Enzyme Digest. 
Reagent Volume ("*) 
PX458 plasmid DNA 20 (1 µg) 
NEBuffer 2 (10x) 4 












Table 2.2.8. KpnI Restriction Enzyme Digest. 
Reagent Volume ("*) 
PTE4254 plasmid DNA 20 (1 µg) 
Cutsmart Buffer 4 




2.2.5.4 Annealing primers  
Two primers were annealed to create a double stranded DNA insert as per Table 2.9. 
For plasmid PX458, primers D10A+3-1 (5’-CACCGCTGTGTGTCTCTCCGCCA-3’) 
and D10A+3-2 (5’-AAACTGGCGGAGAGACACACAGC-3’) were used for cloning. 
For plasmid PTE4254, primers KpnID10A+3-1 (5’-
GCTGTGTGTCTCTCCGCCAGTAC-3’) and KpnID10A+3-2 (5’-
TGGCGGAGAGACACACAGCGTAC-3’) were used for cloning.  
The mixture was subsequently heated at 95 ℃ for 5 minutes and decreased to 25 ℃ at a 
rate of 5 ℃ per minute. The annealed duplex was diluted 1 in 200 in MQH2O and used 










Table 2.2.9. Primer Annealing Mixture. 
Reagent Volume ("*) 
Primer 1 (100 µM) 1 
Primer 2 (100 µM) 1 




2.2.5.5 Plasmid ligation  
Plasmids ligation reactions were made using the digested plasmid and annealed primer 
duplexes described in 2.2.5.4. as per Table 2.10. and incubated at 8℃	overnight before 
being transformed into MC1061 competent bacteria.  
 
Table 2.2.10. Ligation of Plasmid and Annealed Oligos. 
Reagent Volume ("*) 
Cut Plasmid 3 
Annealed primer duplex 2 
5X Buffer Ligase 1 







2.2.5.6 Bacterial transformation  
Twenty µL of MC1061 competent bacteria stock was added to 60-100 ng/µL of ligated 
plasmid DNA and left on ice for 10-15 minutes. This was followed by heat shocking at 
42	℃ for 45 seconds after which samples were returned to the ice for 2 minutes. Three 
hundred and fifty µL of 1 x LB was added to the mixture which was shaken at 37 ℃ for 
45 minutes. Transformed bacteria were then spread and grown on 100 µg/
mL	ampicillin 1 x LB plates overnight at 37 ℃. 
2.2.5.7 Screening for Insertion of annealed primers  
Bacterial colonies were screened for the presence of correctly ligated plasmid using 
Platinum Taq DNA polymerase PCR. One bacterial colony was dipped into 10 µL 
MQH2O and then spread onto 100 µg/mL	ampicillin LB plates overnight at 37 ℃. The 
MQH2O mixture was then boiled at 98 ℃ for 3 minutes. Five µL of this was added to 
the PCR tube containing the PCR mixture outlined in Table 2.11. followed by the 
reaction described in Table 2.12. PCR products were then run on 2 % agarose gel for 40 
minutes at 100 V and imaged on a Molecular Imager® Gel DocTM XR+ and analysed 












Table 2.2.11. PCR Reactions to Check for Insertion of Annealed Primers. 
Reagent Volume ("*) 
PCR Buffer 1 
10 mM dNTP 0.2 
50 mM MgCl2 0.3 
Polymerase Taq 0.04 
U6 Primer (5’-GAGGGCCTATTTCCCATGATTCC-3’) 0.2 
D10A+3-2 or KpnID10A+3-2 0.2 
MQH2O 8.06 
DNA One bacterial colony 
Total 10 
 
Table 2.2.12. PCR Thermal Profile to Check for Insertion of Annealed Primers. 
Temperature (℃) Time (minutes:seconds) Number of cycles 
94 2:00 1 
94 0:30  
52 0:30 30 
72 0:30  
72 2:00 1 





2.2.5.8 PCR product sequencing  
Positively identified colonies were grown in liquid culture and the plasmid DNA was 
extracted as per 2.2.5.2. Thirty ng/µL of plasmid DNA was sequenced using ABI 30xl 
DNA Analyser (Genomic Analysis Services).  
2.2.6 Transfections 
2.2.6.1 Optimising transfection conditions for T-47D cells with PX458 
T-47D cells were seeded at 60,000 cells per well into Corning® Costar® 24 well Tissue 
Culture plates in 0.5 mL of complete T-47D media. Twenty four hours later, cells were 
transfected with 0.5 µg of the PX458 plasmid DNA using TransIT BrCA as the 
transfection reagent. This was done as per the manufacturer’s instructions, as shown in 
Table 2.13.  
Cells were transfected with a range of plasmid DNA to reagent ratios as per the 
manufacturer’s recommendation. Ratios of 1.5:1, 2:1, 2.5:1 and 3:1 transfection 
reagent:DNA were used. The transfection reagent was either left on for the entirety of 
the transfection protocol or removed after 24 hours and replaced with complete T-47D 
media. Cells were analysed 48 and 72 hours post transfection when the reagent was left 
on, and 24 and 48 hours when the transfection reagent was removed. Cells were imaged 
in UV on the Cytell Cell Imaging System followed by analysis using the Cytell cycle kit 
to count the number of nuclei. Transfection efficiencies were calculated by dividing the 
total cell number by the number of GFP positive cells shown to glow green. Each 







Table 2.2.13. Transfection conditions with TransIT-BrCa. 
Reagent Volume for 24 well plate Volume for 10 cm dish 
Complete growth medium 0.5 mL 15.5 mL 
Serum-free medium 50 µL 1.5 mL 
DNA (µg/µL) 0.5 µL 15 µL 
TransIt-BrCa 1 µL - 3	µL 37.5 µL  
 
2.2.6.2 T-47D cell transfections with PX458 plasmid  
T-47D cells were seeded at 60,000 cells per well into Corning® Costar® 24 well Tissue 
Culture plates in 0.5 mL of T-47D complete media. 24 hours later, cells were 
transfected with 0.5 µg of the cloned PX458 plasmid DNA and 0.5 µg of the TOPO31 
plasmid DNA using TransIT BrCA as the transfection reagent. This was done as per the 
manufacturer’s instructions, as seen in Table 2.13. with 2.5 µL of TransIt-BrCa. 24 
hours after transfection, cells were sorted using FACS.  
2.2.6.3 FACS  
48 hours after transfection, 80 µL of 0.05 % trypsin was added to each well for 4 
minutes, this was quenched with 200 µL of T-47D complete media and transferred to 15 
mL Falcon tubes. GFP control cells, negative control cells and sample cells were 
centrifuged at 3,000 x g for 5 minutes. 
Dead control cells were incubated at 65 ℃ for 5 minutes and then centrifuged at 3,000 x 
g for 3 minutes.  
Dead control cells and sample cells were resuspended with 100 µL NIR Zombie dye 
and stored at room temperature in darkness for 15 minutes. Following incubation, these 




Dead cell control, GFP control and negative control cells were resuspended with 300 µL 
solubilisation buffer. Sample cells were resuspended in 1 mL of solubilisation buffer.  
BD FACSAriaTM III was used to isolate and sort GFP fluorescent cells as single cells, 
into Corning® Costar® 96-well Tissue Culture plates containing pre-warmed 
conditioned media collected from growing T-47D cells. This was done at the rate of 
below 100 cells per second. The non-transfected cells were utilised as a negative control 
and heat killed cells stained with NIR zombie dye were used as a live/dead control.  
Once colonies reached 80% confluency they were trypsinised and each individual 
colony transferred to a well in a Corning® Costar® 24 well Tissue Culture plate. Once 
80% confluency was reached in these plates, a single well was transferred to a single 
well of a Corning® Costar® 6 well Tissue Culture plate. Cells were grown to 80% 
confluency and half of the 6 well was used for gDNA extraction as per 2.2.4.1. for 
screening, the other half were seeded into 12.5 cm2 cell culture flasks. Once at 80% 
confluency, cells in the 12.5 cm2 cell culture flasks were frozen in liquid nitrogen for 
future use. 
2.2.6.4 T-47D cell transfections with PTE4254 plasmid  
T-47D cells were seeded at 2 x 106 cells in 100 mm Corning® tissue-culture treated 
culture dishes with 15 mL of T-47D full media. Twenty four hours later cells were 
treated with 50 µg/mL nocodazole for 16 hours. Media containing nocodazole was 
replaced with T-47D full media and left for 1 hour before transfection. Cells were 
transfected with 7.5 µg of the cloned PTE4254 plasmid DNA and 7.5 µg of the 
TOPO31 plasmid DNA using TransIT BrCA as the transfection reagent. This was done 




TransIT BrCA was removed and replaced with T-47D full media containing 0.8 mg/mL 
geneticin for 3 days.  
Cells were grown until colonies could be visualised on the dish and these were lifted 
with trypsin soaked filter paper and transferred to one well of a Corning® Costar® 24 
well Tissue Culture plate. Once 80 % confluency was reached in these plates, a single 
well was transferred to a single well of a Corning® Costar® 6 well Tissue Culture plate. 
Cells were grown to 80 % confluency and half the well was used for gDNA extraction 
as per 2.2.4.1. For screening, the other half were seeded into 12.5 cm2 cell culture 
flasks. Once at 80 % confluency, cells in the 12.5 cm2 cell culture flasks were frozen in 
liquid nitrogen for future use.  
2.2.7 Detection of SNP rs77275268 in transfected cells  
2.2.7.1 High resolution melt  
High resolution melt analysis was used on gDNA extracted from clones in 2.2.6.3. and 
2.2.6.4. using forward primer: HRM rs77275268 5’ (5’-
GCTGGTATTGCGGGTTGTTG-3’) and reverse primer: HRM rs77274268 3’ (5’-
CTCCCCCATACCAGGTGCAG-3’) as per the Table 2.14. with the thermal cycle 












Table 2.14. HRM Reactions. 
Reagent Volume ("*) 
Luminaris colour HRM Master Mix (1X) 10 
Forward Primer (10 ng/µL) 1 
Reverse Primer (10 ng/µL) 1 
MQH2O 3 
Yellow Sample Buffer (1X) 2.5 
Sample DNA (10 ng/µL) 2.5 
Total 20 
 
Table 2.15. HRM Thermal Cycling Profile. 
Step Temperature (℃) Time (minutes:seconds) Number 
of cycles 
Initial denaturation 95 10:00 1 
Denaturation 95 0:10  
Annealing/extension 60 0:10 35-45 
 72 0:10  
Melt 65-95 Increments of 0.02 ℃/s  
 
2.2.8 MiSeq  
2.2.8.1 First MiSeq PCR 
T-47D cells transfected with PTE4254 as per 2.2.6.4. were pooled and gDNA was 




Seq primers 5’ (5’-ACGACGCTCTTCCGATCTTATCCCACGTGTTCCCT-3’) and 
Miseq SNP Seq 3’ (5’-
CGTGTGCTCTTCCGATCTCAAAGCTAAGAACCAGGGATCC-3’) as per Table 
2.16. with the thermal cycle described in 2.17. PCR products were then run on a 1.2 % 
agarose gel for 1 hour at 100 V and imaged on a Molecular Imager® Gel DocTM XR+ 
and analysed using Image LabTM 4.0. 
Table 2.16. First PCR Reaction for MiSeq. 
Reagent Volume (") 
Kapa HS ready mix 5 
Miseq SNP 5’ (100 µM) 0.5 
Miseq SNP 3’ (100 µM) 0.5 




Table 2.17. PCR Thermal Profile for First MiSeq Reaction. 
Temperature (℃) Time (minutes:seconds) Number of cycles 
95 0:30  
55 0:30 34 
72 0:30  
72 2:00 1 





2.2.8.2 Bead clean up  
PCR products were incubated with 1.2x Agencourt AMPure XP beads at room 
temperature for 5 minutes in a 1.7 mL Eppendorf tube. The supernatant was removed 
and beads were washed with 200 µL 80 % ethanol and incubated at room temperature 
for 1 minute before being discarded. This ethanol wash was repeated three times before 
the beads were dried at room temperature for 15 minutes. The beads were resuspended 
with 30 µL MQH2O and incubated at room temperature for 2 minutes. Beads were 
captured by the magnet and the supernatant was collected to be used in the second 
round PCR. The captured DNA was quantified using the Qubit® Fluorometer as per the 
manufacturer’s instructions.  
2.2.8.3 Second MiSeq PCR 
Second round PCR was done with FP19 (5’- 
AATGATACGGCGACCACCGAGATCTACACTTTCACACACTCTTTCCCTACAC
GACGCTCTTCCGATCT-3’) and RP16 (5’- 
CAAGCAGAAGACGGCATACGAGATGGACGGGTGACTGGAGTTCAGACGTG
TGCTCTTCCGATC-3’) as per Table 2.18. with the thermal cycle described in 2.19. 
Table 2.18. Second PCR Reaction for MiSeq. 
Reagent Volume ("*) 
Kapa HS ready mix 5 
FP19 (10 µM) 0.5 
RP16 (10 µM) 0.5 






Table 2.19. PCR Thermal Profile for Second MiSeq Reaction. 
Temperature (℃) Time (minutes:seconds) Number of cycles 
95 0:30  
55 0:30 15 
72 0:30  
72 2:00 1 
4 infinite 1 
 
Second PCR product was cleaned using the same bead clean up as 2.2.8.2. and 
quantified using the Qubit® Fluorometer as per the manufacturer’s instructions. 
2.2.9 Chromatin immunoprecipitation  
2.2.9.1 Cross-linking cells  
Cells were seeded at 10 x 106 cells in 15 cm tissue culture plates and grown overnight in 
MCF-7 full media. The next day, the MCF-7 full media was removed and cells were 
rinsed twice with PBS. Twenty mL PBS and 2 mL 11 % formaldehyde solution was 
then added to give a final concentration of 1 % formaldehyde and incubated at room 
temperature for 10 minutes. This was quenched with 2.5 µM glycerine and incubated at 
room temperature for a further 5 minutes. This solution was removed and cells were 
rinsed twice with PBS. To collect cells, 10 mL PBS was added to the plates and the 
adherent cells were scraped using a Costar® Cell Lifter and transferred to a 50 mL 
FalconTM 50 mL Conical Centrifuge Tube. The plate was rinsed with 10 mL PBS twice 
more to ensure collection of all remaining cells. Collected cells were then centrifuged at 
1,350 g for 5 minutes. The supernatant was removed and the pellets were kept at - 80 ℃ 




2.2.9.2 Cell lysis  
Frozen samples from 2.2.9.1. were thawed on ice and resuspended with 2 mL ChIP lysis 
buffer. This was left on ice for 5 minutes to ensure lysis of the cells. 
2.2.9.3 Sonication  
Four hundred µL of lysed cells was dispensed into 1.5 mL Eppendorf tubes creating 5 
aliquots per sample. These samples were then sonicated at 25 % amplitude, 5 x 10 
second pulses using the Sonics Vibra cell VCX 500 ultrasonic processor. Samples were 
centrifuged at 10,000 g for 10 minutes at 4 ℃	to solubilise sonicated chromatin. 
Supernatant from common tubes were then pooled and quantified using the NanoDrop 
1000 spectrometer as per 2.2.2.3. Fifty µL of soluble chromatin was set aside for 
sonication check and kept at – 20 ℃. The remaining soluble chromatin was kept on ice 
until magnetic beads were ready.  
2.2.9.4 Preclearing  
Fifty µL of magnetic protein G beads were aliquoted into n x 2 Eppendorf® LoBind 
microcentrifuge tubes (Protein) where n is the number of immunoprecipitations per 
sample. Beads were spun at 130 x g for 1 minute at 4 ℃ and the supernatant was 
discarded using a magnetic rack. Beads were then washed with 1 mL beads wash buffer 
(PBS/0.1 % Triton X-100), rotated for 5 minutes at 4 ℃ and centrifuged at 130 x g for 1 
minute at 4 ℃ with the supernatant discarded using a magnetic stand. This wash was 
repeated three times.  
Soluble chromatin was diluted 1:4 in ChIP dilution buffer, normalising if needed to the 
sample with the least amount of chromatin. Four hundred µL soluble chromatin was 
added to 1600 µL ChIP dilution buffer; if necessary the higher concentration chromatin 




to ‘n’ tubes of the washed beads and rotated overnight at 4 ℃. To ‘n’ tubes of washed 
beads, 2 mL of beads wash buffer was added with 10 µL CTCF antibody to all 
Eppendorf tubes except one to act as the no antibody control.  
2.2.9.5 Immunoprecipitation  
The following day, antibody coated beads were washed twice with 1 mL beads wash 
buffer centrifugation at 130 x g for 1 minute 4 ℃, with rotation for 5 minutes at 4 ℃ 
and supernatant removed using a magnetic stand. The precleared chromatin was then 
pooled and an input sample of 100 µL was removed and kept at – 20 ℃. Nineteen 
hundred µL of precleared chromatin was added to antibody coated beads and rotated 
overnight at 4℃.	 
2.2.9.6 Immune-complex collection  
Beads were washed three times with 1 mL 0.1 % SDS-Lysis Buffer with centrifugation 
at 130 x g for 1 minute at 4 ℃, rotation for 5 minutes 4 ℃ and discarding of buffer 
using a magnetic stand. Beads were then washed with 1 mL high salt wash buffer with 
centrifugation at 130 x g for 1 minute at 4 ℃, rotation for 5 minutes 4 ℃ and discarding 
of buffer using a magnetic stand. Beads were then washed with 1 mL lithium chloride 
wash buffer with centrifugation at 130 x g for 1 minute at 4 ℃, rotation for 5 minutes 4 
℃ and discarding of buffer using a magnetic stand. Beads were resuspended in 1 mL TE 
buffer, rotated for 5 minutes at 4 ℃, centrifuged at 130 x g for 1 minute at 4 ℃ with the 
supernatant discarded using a magnetic stand. Beads were resuspended with 200 µL 
freshly prepared ChIP elution buffer. ChIP DNA was eluted from the beads by rotation 
at 37 ℃ for 30 minutes before centrifugation at 130 x g for 1 minute at 4 ℃. Using a 
magnetic stand, supernatant containing eluted chromatin was transferred to a 1.5 




2.2.9.7 De-crosslinking  
Input and sonication check samples were made up to 200 µL with MQH2O. Four µL 10 
mg/mL proteinase K was added to samples and check samples and incubated for 2 
hours at 50 ℃.  
2.2.9.8 DNA purification  
Two hundred µL phenol:chloroform:iso-amyl alcohol (25/24/1) was added to each 
sample and vortexed until milky. Samples were then centrifuged for 10 minutes at 2,000 
x g. The aqueous phase (approximately 125 µL) was transferred to a new 1.5 
Eppendorf® LoBind microcentrifuge tube (Protein). To each sample, 12.5 µL [NaCl] 
and 312.5 µL cold absolute ethanol was added, this was mixed briefly and incubated at 
– 80 ℃ for two hours. Samples were then centrifuged for 25 minutes at 2,000 x g at 4 ℃ 
and the supernatant discarded. Samples were washed with 50 µL 70 % ethanol, 
centrifuged for 10 minutes at 2,000 x g at 4 ℃ and the supernatant discarded. The pellet 
was dried overnight and resuspended in 22 µL MQH2O.  
2.2.9.9 Quantitative real-time polymerase chain reaction (qPCR) 
The input checks, no antibody controls and antibody treated samples were diluted 1:4 
with MQH2O. Five point six µL of master mix as shown in Table 2.20. was added to 4.5 
µL diluted gDNA and added to each well on a MicroAmp® Optical 384-Well Reaction 
Plate in triplicate. For constitutive CTCF binding, CTCF constitutive 5’ (5’-
CTGGTGAAGCCGCCATAGAT-3’) and CTCF constitutive 3’ (5’-
CTCCACCTGTGCCTTGAAT3’) primers were used. For CTCF binding at the SNP 
site, CTCF SNP 5’ (5’-ACACCTGCACCTGTTATGGC-3’) and CTCF SNP 3’ (5’-




Table 2.20. qPCR Reaction for ChIP. 
Reagent Amount ("L) 
KAPA SYBR® FAST Master Mix (2X) Universal 5 
ROX Reference Dye High (50X) 0.2 
Forward Primer (0.1 µM) 0.2 
Reverse Primer (0.1 µM) 0.2 
Total 5.6 
 
A standard curve was created using PXY62 gDNA sonicated to the same average length 
as the samples. This was serially diluted to 15 ng, 1.5 ng, 0.15 ng and 0.015 ng and 
plated in triplicate. A blank control was also plated in triplicate.  
The MicroAmp® Optical 384-Well Reaction Plate was sealed with an Interlab Real 
Time PCR Thermal Seal and centrifuged at 500 x g for five minutes. The plate was then 
loaded into the ABI 7900HT sequence detection instrument and run at cycles outlined in 
Table 2.21. 
Table 2.21. qPCR Thermal Profile for ChIP. 
Stage Temperature (℃) Time (minutes:seconds) Number of cycles 
1 95 10:00 1 
2 95 00:15 40 
 60 01:00  
3 95 00:15 1 
 60 00:15 1 




2.2.9.10 Analysis of qPCR data 
qPCR analysis was performed with SDS 2.4 software with the Minimum Information 
for Publication of Quantitative Real-Time PCR Experiments Guidelines (MIQE 
guidelines) adhered to.  
2.2.9.11 Percentage of Input Analysis 
ChIP-qPCR data was analysed using the percentage of input method so that results can 
be normalised to account for variability. This analysis was undertaken for each sample 
with both primer sets as shown below.  
  
 
The results produced from the equations above provide the percentage of chromatin 
precipitated, normalised to the precleared chromatin. The CTCF result was then 
normalised to the no Ab result to produce the normalised value of CTCF binding for 










3.1 Analysis of Gene expression at 6q25.1 
To investigate the potential influence, the rs77275268 T SNP has on the genes upstream 
of, as well as ESR1, cell lines with and without the SNP were tested to assess how this 
alteration affects the co-expression of the genes of interest. Cell lines used were derived 
from MCF-7 ER+ breast cancer cell line with CRISPR-Cas9 used to introduce the 
variant T allele. These cell lines were then used to investigate the effects of the SNP on 
the expression of the four genes of interest.  
3.1.1 Optimisation of Gene Expression Experimentation  
Cells were deprived of oestrogen (E2) for 3 days prior to seeding and left to settle and 
adhere for 24 hours before RNA was first extracted, at the ‘0 hours’ time point. Half of 
the cells were then re-introduced to E2 at this ‘0 hours’ time point for up to 48 hours. 
Optimisation of seeding density was required to control for the effects of the growth 
signal oestrogen (1 nmol.L-1 E2) on the cell lines. This was needed at these two time 
points to ensure sufficient amounts of RNA could be extracted at ‘0 hours’ and to 
ensure that cells were not over-confluent at ‘48 hours’ as cell-cell interaction can affect 
gene expression.  
3.1.1.1 Cell counts of 0 hours and 48 hours post E2 addition 
To optimise cell seeding into a 6 well plate, cells were seeded at 3 different densities; 
100,000, 200,000 and 250,000 cells per well. Twenty four hours post seeding, half of 
the plates had the cells fixed, permeabilised and DAPI stained and nuclei counted using 
the Cytation 5. 48 hours post addition of 1 nmol.L-1 E2, the cells in the remaining plates 




















Cytation results for the number of cells per well was lower than the intended seeding 
amount (Figure 3.1A.). Conversely, the cell counts of the wells deprived of oestrogen 
(DCC) for 48 hours increased in number faster than was expected based on the seeding 
(Figure 3.1B.).  
Seeding density was found to be optimal at 200,000 cells per well, as sufficient RNA 
could be extracted from cells at the ‘0 hour’ time point and cells were not over-
Figure 3.1. Cytation of Seeding Density in 6 well plates.  
Cytation 24 hours post seeding into 6 well plate (A). Cytation 48 hours post addition of E2 (B). DCC is 





confluent at the ‘48 hour’ time point. This seeding density is anticipated to be used for 
subsequent gene expression analysis experiments.  
3.1.2 Confirmation of rs77275268 SNP Status 
Edited cell lines with a T at the rs77275268 SNP position (DSB10, DSB19 and D10A50 
and control cell lines with a wildtype C at this SNP position (PXY62 and PX459-6), 
generated from the ER+ breast cancer cell line MCF-7, were obtained from a previous 
student (Kane, 2017). These edited and control cell lines were created using CRISPR-
Cas9 genome editing along with homology directed repair. These cell lines had an 
approximately 260 bp region of interest around the SNP amplified by PCR described in 












Figure 3.2. Gel Electrophoresis of genome edited and control MCF-7 derived cell lines with 
region interest amplified via PCR.  
Each cell line was seeded in duplicate into a 6 well plate with gDNA from each plate extracted after 
24 hours. Duplicate samples were amplified via PCR with the forward primer (SNP Seq 5’) and 
reverse primer (SNP Seq 3’). Lane 1: 1kb universal kappa ladder, 2 and 3: MCF-7, 4 and 5: DSB10, 




Each cell line was run in duplicate and produced a band at approximately 260 bp which 
indicated correct amplification of the region of interest containing the rs77275268 SNP 
(Figure 3.2.). The extra band at approximately 50 bp indicated probable primer-dimer 
binding where the forward and reverse primers used for the PCR reaction have 
amplified each other. The cell line D10A5 also produced an unexpected band at 
approximately 280 bp in both replicates, not present in any of the other cell lines.  
3.1.2.1 Sequencing of cell lines 
These amplified gDNA samples were sent for Sanger sequencing by the Genetic 
Analysis Services (University of Otago) to confirm the base at the site of the SNP. Due 
to the unexpected second band in the D10A5 cell lines, sequencing from both the SNP 
Seq 5’ primer and SNP Seq 3’ primer was performed to increase the chances of a 































Figure 3.3. Sequencing of the amplified 260 bp region around SNP in genome edited and control cell 
lines.  
DSB10 (A), DSB19 (B), MCF-7 (C), PX549-6 (D), PXY62 (E), D10A5 forward (F). Forward sequences 
produced using the SNP Seq 5’ primer and reverse sequences produced using the SNP Seq 3’ primer. All 
sequences produced from the forward primer and read on 4peaks software. Black arrow indicates the base at 





Sequencing of all cell lines except for D10A5 produced confident base calls with single, 
high coloured peaks. The sequencing of the edited cell lines (3.3.A, B and F) showed a 
T base at the position of the SNP while the control cell lines (3.3.C, D and E) showed a 
C base at the same position, both indicated by the arrow.  
3.1.2.2 Confirmation of CRISPR Edited D10A5 
The SNP Seq 5’ sequence for D10A5 was of poor quality with the peaks of the 
chromatogram (Figure 3.3F.) significantly lower than the other sequences produced 
(Figure 3.3.A-E). To test experimental failure, the SNP Seq 5’ and SNP Seq 3’ 
sequences for the D10A5 cell line were re-amplified and sequenced a second time using 











Both of the SNP Seq 5’ nor SNP Seq 3’ sequences produced a T at the position of the 
SNP however the low coloured peaks indicated low confidence in the bases called. 
Figure 3.4. Second sequencing for D10A5 forward (A) and reverse complement (B).  
The black arrow indicates the base position of the rs77275268 SNP. Forward sequences produced using 




Although the second 5’ sequence (Figure 3.4.A) was of better quality than the first 
attempt, it was still not of sufficient quality to complete confidence in the sequence. 
Due to the sequencing failure of the D10A5 cell line, further investigation was 
completed to determine the nature of the second band and its likelihood of interference 
in future gene expression experiments. The methodology used for the PCR 
amplification of the region of interest was investigated and modified to test if the 
unexpected 280 bp band was an artefact of the amplification protocol. 
To deduce whether the 280 bp band was preferentially mis-primed by either the forward 
or reverse primer alone the D10A5 gDNA was amplified with only either the forward or 
reverse primers in the PCR reaction. Neither the forward nor reverse primers 
preferentially amplified the unexpected 280 bp product, while the DNA amplified with 
both the forward and reverse primers still had the expected band at 260 bp and the 
unexpected band at around 280 bp (Appendix 7.1.). As this gel failed to provide any 
more information about the band, further modifications were made to the PCR protocol 
to investigate whether the extra band was a result of mis-priming or a legitimately 
primed product. This however did not elucidate any further answers as shown in 
Appendix 7.2. The sequences produced by the SNP Seq 5’ and 3’ primers for D10A5 
resulted in the correct sequence or failed to provide a sequence at all. This was 
confirmed on BLAST with the sequences produced aligning to the expected position on 
chromosome 6 only.  
Although cutting out and sequencing the 280 bp band could potentially have yielded 
further information about the sequence of the 280 bp band, as its presence signified that 
the D10A5 cell line was unlikely to be suitable for continued use, this was not 




the second band and the failure of the sequencing of D10A5, use of this cell line was 
discontinued for future experiments.  
3.1.3  Gene Expression Analysis 
Once optimisation was complete, relative gene expression was tested to investigate the 
effects of the rs77275269 SNP on the relative expression of the genes of interest. To 
analyse the expression of the C6ORFs and ESR1 around 6q25.1 RT-qPCR was used to 
obtain the relative expression of the genes at the different time points with and without 
E2. Experiments were carried out in the presence and absence of E2 to induce variation 
in the gene expression on the basis that the cell lines are all ER+ breast cancer cells. 
RNA extracted from PX549-6 (C) and DSB10 (T), and from PXY62 (C) and DSB19 
(T) over 48 hours and was converted to cDNA to be used in the RT-qPCR protocol 
described in 2.2.3.  Standard curves produced (Appendix Figure 7.3.) allowed extraction 
of quantitative data for the relative expression of the genes. This was normalised 
relative to the geometric mean of the two reference genes used; FKBP15 and PUM1. 
This experiment was repeated three times for both sets of cell line pairs and analysed 
using PRISM 6 software. 































Figure 3.5. Temporal Expression Profile Graphs of Each Gene of Interest Over 48 Hours.  
Relative gene expression in cells with the SNP (DSB10) in red and without the SNP (PX459-6) in black, 
deprived of oestrogen (DCC) and with oestrogen added (E2) over 48 hours. ARMT1 shown in A and B, 
RMND1 shown in C and D, CCDC170 shown in E and F and ESR1 shown in G and H. Graphs contain three 





The relative gene expression of both RMND1 (3.5.A and B) and ARMT1 (3.5.C and D) 
regardless of oestrogen deprivation or addition were not affected by the presence or 
absence of the SNP edit. The temporal relative gene expression line produced from both 
the edited cell line (DSB10) and control cell line (PX459-6) showed no significant 
difference to each other. The relative gene expression of both CCDC170 (3.5.E and F) 
and ESR1 (3.5.G and H) however were affected by the presence or absence of the SNP 
edit regardless of oestrogen deprivation or addition. The difference was shown by the 
change in the temporal lines produced for both DSB10 and PX459-6 in both of the 
genes temporal expression graphs. To confirm this observation, another pair of control 






































Figure 3.6. Temporal expression profile graphs of each gene of interest over 48 hours. 
Relative gene expression in cells with the SNP (DSB19) in red and without the SNP (PXY62) in black, 
deprived of oestrogen (DCC) and with oestrogen added (E2) over 48 hours. ARMT1 shown in A and B, 
RMND1 shown in C and D, CCDC170 shown in E and F and ESR1 shown in G and H. Graphs contain 
three biological replicates and were analysed with a two-way ANOVA. Error bars represent standard error 





The relative gene expression of both RMND1 (3.6.A and B) and ARMT1 (3.6.C and D) 
regardless of E2 deprivation or addition were not affected by the presence or absence of 
the SNP edit. The temporal expression line produced from both the edited cell line 
(DSB19) and control cell line (PXY62) showed no significant difference to each other. 
The relative gene expression of both CCDC170 (3.6.E and F) and ESR1 (3.6.G and H) 
were possibly affected by the presence or absence of the SNP regardless of oestrogen 
deprivation or addition. The difference was shown by the change in lines produced for 
both DSB19 and PXY62 in both of the genes temporal expression graphs. However, the 
change in relative temporal gene expression was not as obvious in ESR1 when 
oestrogen was added. Once again, in this pairing of edited and control cell lines derived 
from MCF-7s, it appeared that the relative expression of ARMT1 and RMND1 were 
unaffected by the SNP, while CCDC170 and ESR1 were. Although this effect was 
somewhat mitigated by the addition of E2 in the case of ESR1 relative gene expression. 
3.1.3.2 CCDC170 Primer Probe Gene Expression Analysis 
Veeraraghavan et al., (2014) found that a fusion can occur between the CCDC170 and 
ESR1 genes resulting in a truncated protein in multiple breast cancer cell lines, 
including MCF-7 (Veeraraghavan et al., 2014). These fusion events were found to be 
with exons 10 and 2 of ESR1 and exons 1, 6, 7, 8, 10 of CCDC170. The primer probe 
set used in the first RT-qPCR for CCDC170 bridged the exon 10-11 boundary which is 
present in the gene fusion. To ensure that the fusion gene was not the cause of the 
apparent grouping of CCDC170 with ESR1 observed, a new primer probe for 
CCDC170 was used that bridged exons 2-3, not involved in the gene fusion event 
compared to the original primer probe. The relative expression of CCDC170 produced 




The correlation of the new and old CCDC170 primers to ESR1 was also compared to 
ensure that any change was not affecting the aforementioned grouping of the relative 












































Figure 3.7. Correlation graphs of the relative expression of the CCDC170 gene using the original 
CCDC170 primer probe (CCDC170) and the new CCDC170 primer probe (CCDC170 (2-3)). 
Correlation of the old CCDC170 primer (CCDC170) and new primer (CCDC170 (2-3) in PX549-6 
deprived of E2 (A), PX549-6 cells with E2 (B), DSB10 cells deprived of E2 (C), DSB10 cells with E2 
(D). ESR1 correlated to old CCDC170 primer probe in PX549-6 cells deprived of E2 (E) and in DSB10 
deprived of E2 (G). ESR1 correlated to new CCDC170 primer probe in PX549-6 cells deprived of E2 (F) 
and in DSB10 deprived of E2 (H).  
r represents the Spearman co-efficient with positive numbers indicating a positive relationship. P 





The relative expression of the CCDC170 gene was positively correlated between the 
two primer probe sets and was statistically significant (p	≤ 0.05) for all the different 
conditions (Figure 3.7.A-D). The relative gene expression produced by the two 
CCDC170 primer probes were also correlated with the exact same spearman r and p 
value in both control cells deprived of E2 (3.7.E and F) and edited cells deprived of E2 
(3.7.G and H). These graphs were also representative of the two primer probes 
correlation to ESR1 in E2 conditions which also had the same spearman r and p value 
for both CCDC170 primer probe sets (Appendix Figure 7.4.). These results confirmed 
that the original primer probe set for the relative gene expression of CCDC170 was not 
being significantly affected by the potential fusion gene and results from this primer 
probe should not be disregarded.  
3.1.3.3 Temporal Expression Profiles over 12 hours 
To investigate whether the observed effects of the SNP occurred due to transcriptional 
changes, the experiment was repeated in the cell line pair PXY62 and DSB19 over 12 
hours. As transcriptional changes tend to occur over a shorter time period than 48 hours, 
having only one time point between 0 and 24 hours as in 3.1.3.1, could have resulted in 
missed relative temporal gene expression changes as a result of transcriptional effects 





































Figure 3.8. Temporal expression profile graphs of each gene of interest over 12 hours. 
Relative gene expression in cells with the SNP (DSB19) in red and without the SNP (PXY62) in black, 
deprived of oestrogen (DCC) and with oestrogen added (E2) over 12 hours. ARMT1 shown in A and B, 
RMND1 shown in C and D, CCDC170 shown in E and F and ESR1 shown in G and H. Graphs contain 
three biological replicates and were analysed with a two-way ANOVA. Error bars represent standard error 





Over 12 hours, there was no change in the general trend of the relative gene expression 
of either RMND1 (3.8.A and B) or ARMT1 (3.8.C and D) regardless of oestrogen 
deprivation or addition. The relative gene expression trends of CCDC170 and ESR1 
diverged dependent on the SNP when deprived of oestrogen (3.8.E and G). However, 
this effect was observed in these genes when oestrogen was added (3.8F and H). Once 
again ARMT1 and RMND1 relative gene expression trends were unaffected by the SNP, 
whereas ESR1 and CCDC170 relative gene expression trends were. To investigate the 
apparent gene grouping of CCDC170 and ESR1, the expression of these two genes over 




















Without the SNP, (control line), both CCDC170 and ESR1 relative gene expression 
trend towards an increase from 6 to 12 hours when deprived of oestrogen (DCC) as 
shown in Figure 3.9.A. When oestrogen is added to the control line (Figure 3.9.B), both 
CCDC170 and ESR1 relative gene expression trend towards a decrease from 6 to 12 
hours post treatment. With the SNP (edited line), both CCDC170 and ESR1 relative 
gene expression trend towards a decrease from 6 to 12 hours when deprived of 
oestrogen (DCC) as shown in Figure 3.9.C. When oestrogen was added to the edited 
Figure 3.9. Temporal gene expression profile of ESR1 and CCDC170 over 12 hours. 
Relative gene expression of ESR1 in orange and CCDC170 in orange over 12 hours. Cells without the 
SNP (control) deprived of oestrogen (DCC) and with oestrogen added (E2) shown in A and B. Cells 
with the SNP (edited) and deprived of oestrogen (DCC) and with oestrogen added (E2) shown in C and 
D. Graphs contain three biological replicates and were analysed with a two-way ANOVA. Error bars 





line (E2), both CCDC170 and ESR1 relative gene expression trend towards a decrease 
from 6 to 12 hours post treatment as shown in Figure 3.9.D. The relative gene 
expression of both ESR1 and CCDC170 had decreasing trends from 6 to 12 hours when 
oestrogen was added, regardless of the presence of the SNP. However, the relative gene 
expression trends of both ESR1 and CCDC170 were in the opposite direction dependent 
on the presence of the SNP from 6 to 12 hours when deprived of oestrogen. This 
showed there was possibly an opposing trend in the relative gene expression of ESR1 
and CCDC170 with an increasing trend without the SNP and a decreasing trend with the 
SNP. 
3.1.4 Chromatin immunoprecipitation  
Chromatin immunoprecipitation (ChIP) was utilised to detect potential differences in 














As only one biological replicate was used, there cannot be confidence that these results 
are biologically reproducible. However, the general trend was that CTCF binding at the 
SNP site (3.10.A) and at the constitutive site (3.10.B), there were possibly higher levels 
of binding in the edited cell line DSB19. Further testing with more biological replicates 
is needed to confirm the observed trend, however supports the notion that changes in 
gene expression could be due to differential CTCF binding. The low amount of CTCF 
binding overall was expected as MCF-7 cells have low residual CTCF binding levels 
overall.  
Therefore, future analysis on the SNP effects on CTCF binding should be conducted 
using an alternative breast cancer cell line with higher residual CTCF.  
Figure 3.10. Quantification of CTCF binding. 
ChIP-qPCR for CTCF was performed on genome edited (DSB19) and control (PXY62) MCF-7 derived 
cell lines. Samples were amplified with primers for the SNP site (A) or a constitutive CTCF binding site 
on chromosome 4 (B). Graphs contain one biological replicate with three different samples as technical 
replicates of the entire ChIP experiment. Error bars represent the standard error of the mean from these 




3.2 CRISPR editing of T-47D cell line 
The CRISPR-Cas9 gene editing tool was utilised previously to introduce the 
rs77275268 mutant T SNP of interest into MCF-7 cells creating the clones used in the 
gene expression analysis described in 3.1. One limitation of the MCF-7 derived cell 
lines is that previous analysis of the MCF-7 cell line has shown that constitutive CTCF 
binding is relatively low, meaning that any experimentation to determine potential 
differences in binding affinity may be difficult to analyse (A. Dunbier, personal 
communication). Therefore, to investigate the hypothesis that differences in relative 
gene expression at the transcriptional hub around 6q25.1 described in 3.1 is affected by 
CTCF binding, another ER+ breast cancer cell line with higher basal CTCF binding 
containing the mutant T SNP of interest would be useful. T-47D cells are an alternative 
ER+ breast cancer cell line with higher constitutive CTCF binding and therefore could 
make a good model to analyse potential differences in levels of CTCF binding. 
CRISPR-Cas9 was once again utilised along with homology directed repair to create 
edited clonal cell lines containing the mutant T SNP rs77275268, derived from the T-
47D cell line.  
3.2.1 Molecular cloning of PX458 plasmid  
The PX458 plasmid with GFP selection was linearised using the restriction enzyme 
BbsI to produce cuts in the plasmid at specific sites highlighted in Figure 3.11. 
Oligonucleotides specific for the target site of DNA intended to be edited were annealed 
together for subsequent ligation into the linearised plasmid and ultimately to act as the 




















Once the plasmid was ligated with the annealed oligonucleotides, MC1061 competent 
bacteria were transformed with the plasmid. Taking advantage of the bacteria’s own 
replication machinery to replicate the cloned plasmid. This plasmid DNA was then 
isolated from the bacteria using the Zymo plasmid purification kit.  
BbsI	(245) BbsI	(267) 
Ligated	Oligos 
Figure 3.11. Plasmid PX458 schematic with the position of the gRNA. 






3.2.1.1 Molecular cloning screen 
Single colony screening of transformed bacteria was performed using primers specific 
for the U6 promotor within the PX458 plasmid and the ligated oligonucleotides. This 
ensured that any PCR products visualised using gel electrophoresis would indicate 
insertion of the ligated oligonucleotides in the right part of the plasmid.  
  
3.2.1.2 Sequencing of molecular clones 
Extracted plasmid DNA from three transformed bacterial colonies shown to be potential 
positives through the colony PCR screen, were then sent for Sanger sequencing by the 
Genetic Analysis Services (University of Otago) to confirm the successful ligation of 
the annealed oligos.  
Figure 3.12. Gel electrophoresis of the colony PCR screen for PX458 plasmid and inserted oligos. 
L: 1 kb universal kappa ladder, +: positive control from a previously cloned in plasmid with a U6 primer and 






All three of the clones sequenced showed the presence of the ligated oligonucleotides, 
indicating the molecular cloning was successful (Figure 3.13.). Clone 10 was selected to 
be used in successive experiments as it produced the cleanest sequencing results.  
3.2.2 Transfections  
For the cloned plasmid to edit cells’ DNA, it must successfully pass through multiple 
membranes and cellular barriers to get into the cell nucleus. This can be done using 
many methods, including transfection, which relies on transfection reagents to aid in the 
delivery of the plasmid into the cell. Previous attempts at transfecting T-47D cells using 
various alternative transfection reagents including Lipofectamine® 2000 and 
FuGENE® HD have been relatively unsuccessful due to low transfection efficiency. 
However recent advances in breast cancer specific transfection reagents have increased 
 
Figure 3.13. Sequencing of three PX458 clones positively identified from Figure 3.12. 
8: clone 8, 10: clone 10, 18: clone 18. Sequences produced from the U6 primer based off the PX458 




this transfection efficiency. TransIT-BrCa was used to insert the PX458 plasmid into T-
47D cells.  
3.2.2.1 Transfection optimisation  
To optimise this method of plasmid delivery, the ratio of transfection reagent to plasmid 
DNA, as well as the length of time the transfection reagent remained on the cells needed 
to be determined. The first round of transfections (Figure 3.14.) had the transfection 
reagent added at different ratios to plasmid DNA and the reagent was left on the cells 
























Cells treated with TransIT-BrCa for both 48 and 72 hours without removal had high 
levels of death, observed through changed morphology captured in the brightfield 
images via Cytation analysis (3.14.A and B) (Kroemer et al., 2009). To increase cell 




Figure 3.14. Transfection efficiency over 72 hours without reagent removal. 
Representative cytation pictures of cells 48 hours (A) and 72 hours (B) after transfection. Control: 
untransfected cells, ratios shown indicate the ratio of transfection reagent to plasmid DNA. Graphic 






















Considering both the transfection efficiency and cell viability, the transfection ratio of 
2.5:1 (reagent:DNA) with removal of the reagent 24 hours post transfection was 
determined to be optimum and carried forward for subsequent experiments.  
A 
B 
Figure 3.15. Transfection efficiencies 24 and 48 hours after transfection with removal of the 
transfection reagent. 
Representative cytation pictures of cells 48 hours (A) after transfection. Control: un-transfected cells, ratios 
shown indicate the ratio of transfection reagent to plasmid DNA. Graphic schematic of the transfection 





3.2.3 Fluorescence activated cell sorting. 
Transfected T-47D cells were sorted into Corning® 96 well plates with a single cell per 
well using fluorescence activated cell sorting (FACS) based on insertion of the GFP 




Only transfected cells that met all three criteria produced from the manual gating shown 
in Figure 3.16. were sorted into a total of four Corning® 96 well plates for further 
propagation. Cells were grown up into Corning® 24 well plates and subsequently 
Corning® 6 well plates. Half of the cells in each well of the Corning® 6 well plates had 
gDNA extracted to be used for CRISPR screening. 
Figure 3.16. FACS data of transfected T47D cells. 
A: Manual gating of cells for the selection of an appropriately sized single T47D cell, B: manual gating of 
cells for the selection of live cells based on P4 population showing negative fluorescence for zombie dye 




3.2.4 CRISPR screening optimisation  
To screen the various clones produced from the FACS, screening techniques required 
optimisation to ensure a specific and high throughput process.  
3.2.4.1 High Resolution Melt analysis  
High resolution melt (HRM) analysis measures melting temperature of a particular 
DNA molecule and produces a characteristic melt curve that can then be used to discern 
sequence differences between PCR products (Han et al., 2012). HRM was used to 
screen the clones for the presence of the SNP (A-T) compared to wildtype (C-G).  
3.2.4.2 High resolution melt controls 
The MCF-7 derived clones that were known to contain edits at the SNP site were used 
for optimisation of the HRM analysis to ensure sufficient sensitivity for the distinction 




The known T homozygote cell line DSB10 and the known C homozygote line PX549-6 
were used to create a pseudo-heterozygote control by mixing the two DNA samples 
Figure 3.17. Control samples high resolution melt curve. 
Green: edited control DSB10 cell line DNA (T), blue: unedited control PX549-6 cell line DNA (C), 




50:50 as shown in Figure 3.17. The HRM melt curves could be separated into distinct 
groups by the gene scanning program on the HRM analysis software. This showed that 
HRM was suitable for use in screening the gDNA extracted from the CRISPR clones 
propagated following FACS.  
3.2.5 HRM screen of generated CRISPR clones 
The 109 clones that were able to be grown up to 6 well confluency had gDNA extracted 
and were screened using HRM. The first set of 93 clones were analysed on a Corning® 
96 well plate along with a no template control and a T homozygote (DSB10) and C 











 Figure 3.18. High resolution melt curves for FACS generated clones. 
A: HRM screening of first 93 FACS generated clones, green: T homozygous control, blue: C 
homozygous control, other colours: unknown. B: HRM screening of the last 13 FACS generated clones, 
green: T homozygous control, blue: C homozygous control, red: C/T heterozygous control, other 
colours: unknown. C: HRM screen of clones from A and B shown to be homozygous T, blue: T 




Based on the normalised and shifted melt curves generated, the gene scanning program 
on the HRM analysis software auto-grouped each sample into distinct groups. 
Stringency was applied based on the knowledge that DSB10 was definitely different to 
PX549-6, and therefore the stringency could not be low enough to allow confusion 
between these two groups. Based on these parameters, the normalised and shifted 
melting curves and difference plots were produced in Figure 3.18. The first 93 clones 
screened are shown in Figure 3.18.A were grouped into four separate groups. DSB10, 
the known T homozygote sample was assigned green along with 3 other clones from the 
FACS cell sorting; 1A6, 3H2, 3H9 and 3H12 indicating potential successful edits. 
PX549-6, the known C homozygote sample, was assigned blue along with majority of 
the other DNA samples from the clones FACS sorted indicating CRISPR editing had 
not occurred. Two other groups were formed based on the parameters set for the auto-
grouping shown in red and purple. These could be due to the formation of heterozygote 
clones and/or different double-stranded breaks that were repaired by non-homologous 
end joining resulting in unique fusions/insertions or deletions. A heterozygote control 
was not included in this plate.  
Figure 3.18.B showed the second round of HRM analysis on the remaining DNA 
extracted from the 16 FACS clones that could not fit on the first 96 well plate. This 
analysis included the pseudo-heterozygote control as another known ‘group’ to compare 
the FACS clone gDNA to. This resulted in three groups based on the normalised and 
shifted melt curves. The control T homozygote was assigned green and did not include 
any of the FACS clones. The control C homozygote was assigned blue and included 




heterozygote control was assigned red and included two FACS clones, 2B5 and 3G4, as 
potential heterozygotes produced from the CRISPR editing.  
Additional HRM analysis of the apparent T homozygote grouped clones as well as the 
heterozygote grouped clones was analysed to confirm the candidate homozygous edited 
clones (Figure 3.18.C). The first screen did not include the heterozygote control, 
therefore the T homozygous samples were re-analysed alongside the heterozygote 
control in this screen. From this ‘confirmation screen’, clones 1A6, 3H2, 3H12, 1E7, 
3A9, 3G4, 2E10 and 3H8 were grouped with the T homozygote control.  
As clones 1A6, 3H2 and 3H12 were grouped as potential T homozygous edits in two 
different screens and fit the FACS parameters as shown in Figure 3.19., these 3 clones 




Figure 3.19. FACS gating of clones to be sequenced. 
Potential homozygous T edits 1A6 (green), 3H2 (blue), 3H12 (red) shown within the manually gated 




3.2.6 Sequencing of potential T homozygous clones 
Prospective T homozygous edited clones that were generated via HRM assay screening 
in 3.2.5. were then sequenced to confirm the presence of the T SNP. The three clones 
that were grouped with the T homozygote in two screens; 1A6, 3H2 and 3H12 were 
amplified and cleaned before being sequenced using the Sanger method by the Genetics 
Analysis services (University of Otago) to provide an accurate sequence of the 











None of the potential T homozygote clones from the HRM screening contained a T at 
the position of the SNP as shown in Figure 3.20. A second, unexpected sequence was 
observed in the chromatograms produced from clones isolated using FACS Figure 3.20. 
that was not due to heterozygotic CRISPR editing. This was manually extracted from 




Figure 3.20. Sequencing of HRM confirmed T homozygous FACS clonal cell lines. 
Forward sequences produced from the gDNA of the clonal cell lines were produced using SNP Seq 5’. 
A: clone 1A6, B: clone 3H2, C: clone 3H12. All sequences were read on 4peaks software. Black arrow 






Due to the fact that the ‘second sequence’ observed in each of the clones derived from 
the FACS was exactly the same, it was unlikely to be due to non-specific CRISPR 
editing. T-47D gDNA was extracted and sequenced in the same way to check if the 







Figure 3.21. Manually extracted second sequence from FACS clones sequences. 







The sequences from T-47D and 1A6 DNA (Figure 3.22.) have the same second 
sequence observed in all of the clonally derived cell lines sequenced in Figure 3.20. It is 
therefore more likely to be an artifact of the T-47D cell line that had been passed down 
to the subsequent clonal cell lines that have undergone CRISPR, rather than a result of 
off target CRISPR editing. As the same primers and conditions were used to sequence 
the MCF-7 derived cell lines in Figure 3.3 it was unlikely that this second sequence was 
due to contamination of the primers or master mix.   
 
 
Figure 3.22. Sequencing of T47D gDNA and 1A6 gDNA. 
A: T-47D forward sequence, B: 1A6 forward sequence. Forward sequences in both cases were 
produced using the SNP Seq 5’ primer. All sequences were read on 4peaks software. The black arrow 




To investigate this second sequence further, BLAST alignment against the human 
genome was performed. When aligned to the human genome on BLAST, the second 
sequence had no significant alignments, even with the lowest stringency settings. The 
second sequence was then aligned to ‘non-human’ genomes and a significant alignment 
was found with 150 of the bases. The top alignment found was to a BAC clone in a 
paper by Tomita et al., 2015 that had a max score of 118, query cover 100 % and 
percentage identity of 82.28 % (Tomita et al., 2015). The paper by Tomita et al., 2015, 
showed the second sequence most significantly aligned to the BAC clone 404G5, a 
schematic of which is shown in Figure 3.23.B (Tomita et al., 2015). 
 
 
The schematic of the position this BAC clone sequence was in the same region as the 
rs77275268 SNP of interest, between C6ORF96/CCDC170 and ESR1.  
3.2.7 Further investigation into the T47D cell line DNA at 6q25.1 
To determine whether the second sequence could be affecting the region of interest, 
multiple sequencing platforms and analysis sites were utilised for further investigation.  
Figure 3.23. Schematic of 404G5 BAC clone position in the genome from Tomita et al., 2015. 
The green bars show the length of the 404G5 BAC clone with the genes in the area shown with 




3.2.7.1 Alignment of sequences to the human genome and BAC clone 
CLC main workbench was used to align the main T-47D sequence, 1A6 clone sequence, 
T-47D second sequence and the BAC clone sequence (Crona et al., 2015). CLC main 
workbench was also used to align T-47D main sequence, 1A6 clone sequence, T-47D 
second sequence and the area of chromosome 6 around the rs77275268 SNP.   
 
 
The second sequence aligned perfectly to the BAC clone as shown in Figure 3.24.A, 
whereas the main sequences from T-47D and the 1A6 clone aligned very poorly to this 
sequence. The main sequences from T-47D and the 1A6 clone aligned perfectly to the 
expected region of chromosome 6, however the second sequence did not (Figure 
3.24.B). Supporting the notion that the second sequence may not be human genomic 
Figure 3.24. CLC main workbench alignments of original and second T47D sequences. 
Alignment of the main T-47D and 1A6 sequences and the second sequence found in both cell lines to the BAC 
clone (A) and to the region of chromosome 6 rs77275268 is found (B). BAC clone (404G5) sequence provided 




DNA as it did not align to the human reference genome on chromosome 6 at the 




The second sequence was queried on UCSC genome browser and 61 of the bases were 
aligned to a long interspersed element (LINE) on chromosome 6, in the same area of the 
SNP, at 6q25.1 (Figure 3.25.). When aligned to the manually written second sequence, 
the portion that aligns to the LINE is seen to be the last 61 of the 154 bases. 
3.2.7.2 Second sequence impact on HRM results 
The presence of a second sequence in the region of DNA amplified by the HRM 
primers would affect the screening process by causing differences in the melt curves. To 
confirm that this was not the case, the T-47D gDNA was sequenced using the HRM 





Figure 3.25. UCSC and BLAST alignment and investigation of the second sequence. 
A: the 61 bases aligned on BLAST against the second sequence. B: UCSC alignment of 61 bases of the 












The chromatogram shown in Figure 3.26. was not as clean as previous chromatogram 
figures, this could be due to the fact that the PCR product created by the HRM primers 
is only 98 base pairs. Therefore, sequencing of this product was more difficult than 
longer PCR products. However, it clearly showed no second sequence indicating the 
HRM analysis was not effected by primer off targets or the potential presence of 
another sequence.  
Based on these results from the second sequence, it was concluded that it was most 
likely due to non-specific priming and not a genetic rearrangement or anomaly in that 
area, that would potentially effect CRISPR editing. Therefore, the T-47D cell line was 
continued to be used for CRISPR editing experiments. 
3.3 CRISPR with PTE4254  
As CRISPR editing of T-47D cells using GFP selection with PX458 did not produce 
any successfully edited T homozygote clones, a new plasmid with antibiotic selection 
was chosen for the next attempt at editing. Previous experiments at CRISPR editing 
with antibiotic selection had been done with puromycin selection plasmids, however 
this was unsuccessful as this antibiotic found to be too toxic to the T-47D cells at any 
Figure 3.26. Sequencing of the 98 bp amplified region around SNP in T47D cells gDNA. 
Forward sequence of T47D cell gDNA produced from the HRM primers. The forward sequence was produced 
from the 5’ rs77275268 HRM primer and read on 4peaks software. Black arrow indicates the base position of 




concentration. PTE4254 plasmid was chosen as it has geneticin (G418) selection which 
has been previously produced successfully edited T-47D cells using CRISPR. 
Therefore, G418 was used to increase the proportion of transfected cells and hopefully 
increase the overall efficiency of the CRISPR editing.  
3.3.1 Cloning of PTE4254 
The restriction enzyme KpnI was used to linearise the PTE4254 plasmid and allow for 
insertion of the same annealed oligonucleotides as in 3.2.1. To align with the overhangs 
produced from KpnI restriction enzyme, the oligonucleotides were altered to include 
pseudo KpnI cut sites on either end for successful ligation into the KpnI cut sites 
created. These new oligonucleotides were then annealed together and ligated into the 
plasmid so that the end result produced the same insertion as in section 3.2.1. Schematic 



















The cloned plasmid PTE5254 was transformed into competent MC1061 bacteria. After 
transformation, transformed bacterial colonies were screened using colony PCR to 




















Clones 8B, D, E and K were positive with bands at the expected size of about 260 bp 
(Figure 3.28.). As clone 8D had the strongest band at 260 bp it was sent for Sanger 
sequencing by the Genetics Analysis services (University of Otago) to confirm 
successful ligation.   
 
 
Figure 3.28. Gel electrophoresis of the colony PCR screen for PTE4254 plasmid and inserted oligos. 
L: 1 kb universal kappa ladder, 8A-L: single bacterial colonies from clone 8, -: negative control from non-
ligated PTE4254 plasmid. 
Figure 3.29. Sequencing of clone 8D from PTE4254 cloned plasmid. 




The sequence of clone 8D showed the ligated oligonucleotide, indicating successful 
ligation of the annealed oligonucleotides into the correct site of the PTE4254 plasmid 
(Figure 3.29.).  
3.3.2 Antibiotic selection  
As the PTE4254 plasmid can be selected for by G418, the lowest concentration at which 
maximum cell death occurred was analysed using an MTT assay. This assay was used 
to determine at which concentration T-47D cells were killed 6 days after initial 
selection. The antibiotic was replaced every 3 days.  
 
From the MTT assay, 0.8 mg/mL was chosen as the concentration of G418 to be used 
(Figure 3.30.). Cell death between 0.8 mg/mL and 1.2 mg/mL was not significantly 
changed, while 0.8 mg/mL had significantly more cell death than the lesser 
concentration 0.4 mg/mL.  
Figure 3.30. MTT assay for T-47D cells treated with G418. 





T-47D cells were transfected with the successfully cloned 8D from 3.3.1. and the repair 
DNA sequence in the same method as used in 3.2.1.  
3.3.3.1 HRM with PTE4254  
 
 
Figure 3.31. shows normalised and shifted high resolution melt curves of the three 
known controls, C homozygote, T homozygote and C/T pseudo-heterozygote generated 
from 50:50 mixture of PXY62 (C/C) and DSB10 (T/T). None of the PTE4254 geneticin 
selected clones were grouped with the T homozygote control, clone A5 was however 
grouped with the heterozygote control, indicating potential heterozygotic CRISPR 
editing occurred in this clone.  
3.3.4 Miseq 
As there were no positives for a T homozygote, MiSeq sequencing was used to check 
the efficiency of the CRISPR editing. The MiSeq machine sequences thousands of reads 
from the pool of cells that underwent CRISPR. These reads can be used to give an 
Figure 3.31. High resolution melt curves for PTE4254 generated clones. 
Grey: C homozygote control (PXY62), pink: T homozygote control (DSB10), blue: C/T heterozygote control, 




indication as to whether the methodology was working at all, or if changes and/or re-
calculations needed to be made to this approach. The sequence reads produced from the 
MiSeq were analysed using command line code found in Appendix 7.5. and 
subsequently interpreted using IGV software. The resulting calculations for the number 
of reads containing each base at the SNP position was extracted from IGV and 
represented as a pie chart in Table 3.1.  
 
Table 3.1. Number of reads from the MiSeq analysis. 
A C G T 
7 42016 2 13 
 
From a total 42,038 reads at the SNP position, only 13 contained the edited T version 
which is equivalent to 1 in every 3,234. Therefore, the current CRISPR methodology 












4 Discussion  
Elucidating the genetic mechanisms that drive breast cancer development is of great 
importance, not only to aid in the development of prognostic and diagnostic tools, but 
also disease therapy. RMND1, ARMT1 and CCDC170 as well as ESR1 have been 
previously investigated and found to be correlated both in vitro and in vivo (Dunbier et 
al., 2011). The SNP rs77275268 is found at the same genomic region as these genes and 
has been linked to increased susceptibility and treatment resistance Cuddapah et al., 
2009 found that most CTCF barriers occurred in intergenic regions as the SNP of 
interest (Cuddapah et al., 2009). Further to this, the location of the SNP within a CTCF 
binding site suggests that altered chromatin looping or 3D arrangement may be 
important for the mechanisms by which the SNP induces increased genetic 
susceptibility to breast cancer (Zuin et al., 2014). CTCF regulates chromatin structure 
by forming loops which can link and un-link genes to promotors and other transcription 
factors affecting gene expression (Zuin et al., 2014). Not only does CTCF influence 
chromatin structure via the introduction of DNA loops, but the directionality of the 
CTCF protein adds an extra layer of organisation for the 3D structure of chromatin and 
control of gene expression (Yin et al., 2017). The direction of the CTCF binding site is 
established through specific bonds within the core sequence, co-ordinated through 
interaction with the CTCF zinc fingers (Yin et al., 2017). Adding to this proteins 
complex mechanisms, it has also been shown to interact directly and indirectly with 
other DNA modifying proteins as well as itself. While CTCF has previously been 
implicated in carcinogenesis, its precise role in the initiation of progression is still 




thought to be involved in genetic susceptibility as well as treatment resistance for ER+ 
breast cancer but the mechanisms are yet to be determined.  
4.1 Optimisation of Gene expression experiments 
The cell counts from the Cytation analysis in Figure 3.1. showed fewer cells than 
expected from seeding. The fact that the Cytation 5 analyses the cells in a square area 
may contribute to this disparity. As wells in the 6 well plate are circular, the square 
analysis meant that cells around the outside of the well were not counted. In addition, 
some of the cells seeded into the well may not have adhered within the 24 hours the 
plates were left to sit which also could have contributed to the disparity. The increase in 
the DCC cells over 48 hours could be because, despite the deprivation of E2, residual 
growth factors may reside within the cells causing continued growth. The cells that had 
E2 added to the wells 24 hours post seeding had a 1.5-2 fold higher number of cells than 
those deprived of E2. 
4.2 Relative gene expression of the C6ORFs and ESR1 
Results from the temporal gene expression profiles produced from the RT-qPCR 
analysis (Figures 3.5., 3.6., 3.8.) showed similar expression trends between CCDC170 
and ESR1 and also in ARMT1 and RMND1. These results provide more information that 
aid in ascertaining the potential mechanisms for this SNP. The observed co-expression 
of the two pairs of genes was also apparent between 0-12 hours. Over this shorter time 
series, transcriptional factors and elements are more likely to be acting. Co-expression 
as observed, during this shorter time point strengthens the notion that transcriptional 
events at this area are being affected by the SNP as transcriptional events occur in this 




Variation between the control cell lines (PXY62 and PX459-6) and the edited cell lines 
(DSB10 and DSB19) was observed in the temporal expression profiles despite having 
the same genome at 6q25.1 – the area of interest. All of these clones were established 
from an MCF-7 population rather than a monoclonal MCF-7 population. Therefore, any 
indels and/or rearrangements in the genome of the cells within the MCF-7 original 
population could have been carried through into the established clonal lines that could 
also affect the temporal gene expression profiles. Alternatively, differences in 
undetected off-target CRISPR editing could have occurred independent of the specific 
SNP which could have affected the temporal gene expression profiles. Not only is this 
region a CTCF binding site, but it has also been associated with a ‘super-enhancer’ in 
MCF-7 cells (Dunning et al., 2016). The complexity of this region could explain the 
variability observed in the temporal expression profiles (Figures 3.6 and 3.7) and 
exemplifies the need for the cell cycle synchronisation to minimise confounding cellular 
mechanisms associated with proliferation.  
One potential mechanism for the observed effects of the SNP on the expression of the 
C6ORFs and ESR1 is that the T instead of a C results in a de-methylated CTCF binding 
site. Methylation status is known to affect protein binding and this change could result 
in altered CTCF binding (Bell and Felsenfeld, 2000). Methylation is known to be a 
regulator of CTCF binding and function, specifically in the imprinted H19/Igf2 locus 
(Holwerda and de Laat, 2013). In the H19/Igf2 region it has been shown that CTCF 
binds to the un-methylated maternal imprinting control region (ICR) but cannot bind 
nor have the same regulatory control on the methylated ICR found on the paternal allele 
(Holwerda and de Laat, 2013). As the rs77275268 SNP confers a change from a C to a 




be methylated while the C can. This could therefore result in altered CTCF binding as 
seen in the H19/Igf2 locus. This potential mechanism is shown in Figure 4.1. 
 
The observed co-expression of ARMT1 with RMND1 and CCDC170 with ESR1 could 
be explained by a different chromatin looping pattern caused by altered CTCF binding 
due to a change in methylation status at the SNP site. When the C is changed to a T, 
Figure 4.1. T variant of the rs77275268 SNP directly altering CTCF binding resulting in 





CTCF binding could be altered resulting in a subsequent change in the looping of the 
surrounding genes causing the grouping pattern seen (Figure 4.1). 
CTCF alone may not however, be sufficient to mediate the barrier function of chromatin 
insulators and a secondary event may be required for specificity (Cuddapah et al., 
2009). The addition of E2 altered the temporal expression profile and the separation of 
the genes into the two aforementioned groups. This could be because E2 may be acting 
as the necessary ‘secondary event’ required for specificity and therefore its presence or 
absence may explain the differences observed in these temporal expression profiles. By 
acting as a ‘secondary event’ or co-factor, E2 could be affecting the binding of CTCF to 
the DNA sequence or its interaction with other proteins necessary for DNA 3D 
arrangements. Conversely, oestrogen may not be directly interacting to the protein or 
the DNA sequence, but it could be mitigating some of the apparent effects on ESR1 and 
CCDC170 through more global effects.  
An alternative, albeit not dissimilar, hypothesis is that the change from a methylated C 
to an un-methylated T could affect the binding of a zinc finger of the CTCF protein. 
Renda et al., (2007) have previously found that particular zinc fingers of the CTCF 
protein are responsible for core consensus sequence recognition while others are 
responsible for the recognition of domains outside the consensus region (Renda et al., 
2007). As CTCF has also been found to mediate protein-protein interactions, altered 
zinc finger binding could result in altered protein recruitment, including recruitment of 







When the SNP has a C base which can be methylated, it is predicted that the CTCF zinc 
finger bound at that position in the DNA can no longer bind. The unbound zinc finger is 
predicted to recruit an unknown protein, potentially enhancer or repressor 1 as shown in 
Figure 4.2. However, when the SNP has a T base which cannot be methylated, the 
corresponding zinc finger of the CTCF protein can bind. This bound zinc finger results 
Figure 4.2. T variant of rs77275268 SNP affecting CTCF zinc finger binding resulting in indirect 




in the recruitment of a different, potential enhancer or repressor 2 as shown in Figure 
4.2. CTCF has been previously shown to bind proteins from a range of functional 
groups including activators and repressors as shown in the theoretical schematic above 
(Figure 4.2.) (Zlatanova and Caiafa, 2009).  
4.3 ChIP 
To further investigate the expression changes as above, ChIP was used to investigate 
any changes in the binding of CTCF through qPCR analysis. The constitutive binding 
site had a large difference between the edited and the control cells, therefore, it is not 
possible to determine whether binding of CTCF at the SNP site was being specifically 
effected. However, these initial results suggest that the SNP may have an effect on 
CTCF binding. Whether that be through direct CTCF binding at the SNP region or 
through global genomic effects cannot be elucidated and more biological reps need to 
be generated for confidence in this observation. The observed changes in CTCF 
expression levels also further support the unpublished data generated by Kane 2017 
(Kane, 2017). The observed decrease in CTCF binding at the SNP with the T variant 
could provide the mechanism for the aforementioned co-expression of ESR1 and 
CCDC170 and also RMND1 and ARMT1. As there are between 15,000 and 40,000 
CTCF binding sites within the genome, dependent on cell type, changes in the binding 
of one site could create different genomic looping through CTCF dimer interactions 
with an alternate site in the genome (Phillips and Corces, 2009b).  
As the expression levels of CTCF in both cell lines containing both variants of the 
rs77275268 SNP were low, changes are less apparent. To better elucidate the predicted 
changes of CTCF binding at the SNP, an alternative breast ER+ breast cancer cell line 




4.4 CRISPR  
Currently, most studies have focused on HDR-based strategies similar to those used in 
this project. However, the rate of integration of a specific mutation has been reported to 
be low, with HDR in human cells intrinsically inefficient (He et al., 2016). These 
properties result in generation of very few target clones amid a large number of random 
integrations. This influenced the large number of clones that were screened, with the 
hypothesis that the larger the number of clones – it would be more likely to find a 
correctly mutated clone.  
It was concluded that the second sequence found in the T-47D cells was mostly likely to 
be the result of mis-priming by the sequencing primers used. This was confirmed by the 
investigation performed in section 3.2.7. Using whole genome sequencing of T-47D 
cells, no major genomic rearrangements or indels were discovered in the region of 
interest (Dixon et al., 2018). The alignment of a LINE, a highly repetitive genomic 
element, means that the primers could have been priming to a LINE from multiple, 
various places within the genome. The repetitive nature also means that further 
investigation would be more difficult compared to investigation into unique sections of 
genomic material. However, the fact that this repetitive element was picked up by the 
primers in the T-47D cells and not in the MCF-7 cells, despite the same primers being 
in use, was still unexpected. For the purposes of future CRISPR editing of the cell line 
however, it would not be necessary for further investigation to be performed.  
The low number of successfully edited cells as shown in Figure 3.27. indicate that the 
cells are not undergoing HDR to incorporate the SNP edit via the repair DNA. Before 
another attempt to edit, changes should be made to the methods of this CRISPR system. 




cycle to increase the rate of HDR, NHEJ can still occur at this phase of the cell cycle. 
Despite being in the right phase for HDR, the cells could still be undergoing NHEJ 
more frequently as this pathway is generally preferential for DNA repair due to its 
simplicity within the cell. Although the second sequence was determined to be due to 
the sequencing primers mis-priming as aforementioned, it is possible that during the 
propagation of the T-47D cell line used, it has acquired unique mutations in this area 
not found in the cells processed for the WGS. Further investigation into the area of 
interest could help to rule out complexities in the region of DNA as contributing to this 
low editing efficiency. Alternatively, another ER+ breast cancer cell line with higher 
CTCF binding could be used for future CRISPR work.   
4.5 Future Directions 
To confirm the hypothesised role of CTCF binding in this area, more biological 
replicates of ChIP need to be performed to ascertain protein binding in the area. 
Subsequent testing of cancer hallmark characteristics such as invasiveness, DNA 
damage and proliferation could then be analysed to identify how this SNP may be 
influencing other genes in the cells. As chromatin structure is suspected to be altered by 
this SNP, it is plausible that this change could affect a wide range of genes, potentially 
contributing to the increased genetic susceptibility. By characterising the global changes 
of the cells associated with the SNP, it may help to elucidate the mechanisms by which 
it confers increased susceptibility to breast cancer and treatment resistance.  
Determining the potential methods by which this SNP affects the cell globally could 
prove very useful. Mechanisms of transformation from healthy cells to cancer cells 






To summarise, research suggests that the expression of the genes at the transcriptional 
hub at 6q25.1 is affected by the rs77275268 SNP. The T variant of this SNP confers co-
expression of ESR1 and CCDC170 as well as co-expression of ARMT1 and RMND1. 
Preliminary findings suggest a role for CTCF in the co-expression observed, indicating 
that chromatin structure could be implicated in the mechanism behind this observation. 
However, low residual levels of CTCF in the MCF-7 cells restrict analysis of the 
predicted change in binding at the SNP site. Current CRISPR techniques utilised to 
produce a SNP edited T-47D cell line are not efficient enough to continue with, and 
require further optimisation. Overall, data presented in this project suggest that the 
rs77275268 SNP could be involved in the associated increased risk of breast cancer, 
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7.1 Protocols for solutions  
PBS 
1 x PBS tablet dissolved in 100 mL MQH2O, then autoclaved to sterilise. 
Trypsin 
0.05 % trypsin was made by diluting 0.5 % Trypsin 1 in 10 in PBS 
Nuclear Lysis Buffer 
20 mM Tris pH – 7.5, 50 mM EDTA, 1% SDS, made up to 50 mL MQH2O. 
2% Agarose Gel 
2 g Agarose low EEO added to 100 mL of TAE buffer and heated until dissolved. 
4% Agarose Gel 
4 g Agarose low EEO added to 100 mL of TAE buffer and heated until dissolved. 
Sterile Sorting Buffer 
1 x PBS, 2 mM EDTA, 25 mM HEPES pH – 7, 1 % FBS 
11 % Formaldehyde Solution 
50 mM Hepes-KOH pH – 7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 11 % 
formaldehyde, made up to 10 mL MQH2O. 
ChIP Lysis Buffer 
50 mM Tris-HCl pH – 8, 1 % SDS, 10 mM EDTA, protease inhibitors, made up to 50 
mL MQH2O. 
ChIP Dilution buffer 
16.7 mM Tris-HCl ph – 8, 0.01 % SDS, 1.1 % Triton X-100, 1.2 mM EDTA, 16.7 mM 
NaCl, protease inhibitors, made up to 50 mL MQH2O. 




50 mM Hepes-KOH pH – 7.5, 150 mM NaCl, 1 mM EDTA, 1 % Triton X-100, 0.1 % 
sodium deoxycholate, 0.1 % SDS, made up to 500 mL MQH2O.  
High Salt Wash Buffer 
50 mM Hepes-KOH pH – 7.5, 350 mM NaCl, 1 mM EDTA, 1 % Triton X-100, 0.1 % 
sodium deoxycholate, 0.1 % SDS, made up to 500 mL MQH2O. 
Lithium Chloride Wash Buffer 
10 mM Tris pH – 8, 250 mM LiCl, 1 mM EDTA, 0.5 % Nonidet P-40, 0.5 % sodium 
deoxycholate, made up to 250 mL MQH2O. 
ChIP Elution Buffer 
50 mM Trist pH – 8, 10 mM EDTA, 1 % SDS, made up to 1 mL MQH2O.  












Figure 7.1. Gel electrophoresis for D10A5 amplified with forward and reverse primers alone and both 
primers. 
1: 1 kb universal kappa ladder, 2: D10A5 dNA with SNP Seq 5’ primer and SNP Seq 3’ primer, 3: D10A5 



























Figure 7.2. Gel electrophoresis for D10A5 with differing amplification parameters. 
D10A5 DNA performed with an annealing block, 1: 1 kb universal kappa ladder, 2: 60 oC, 3: 60.8 oC, 4: 62.4 
oC, 5: 64.7 oC, 6: 67.6 oC, 7: 70 oC, 8: 71.4 oC, 9: 72 oC (A).  
DNA from all cell lines annealed at 60 oC 1: 1 kb Universal Kappa ladder, 2: MCF7, 3: DSB10, 4: PXY62, 5: 
PX549-6, 6: D10A5, 7: DSB19 (B).  
DNA from the original dilution of DSB10A5 and DSB10 and newly diluted DNA from these cell lines, 1: 1kb 
Universal Kappa ladder, 2: D10A5 original dilution, 3: DSB10 original dilution, 4: D10A5 new dilution, 5: 
DSB10 new dilution. Forward sequences produced using the SNP Seq 5’ primer and reverse sequences 
















Figure 7.3. Representative qPCR standard curves. 
A: ARMT1 standard curve, B: CCDC170 standard curve, C: ESR1 standard curve, D: FKBP15 standard 






7.5. Miseq Code 
Step 1: Create the necessary files for analysis  
• Primer.fasta  
• sgRNA 
• IllAdapter 
• The actual sequencing files from Miseq saved as: Injected_R1 and Injected_R2 
Step 2: Run quality control 
Create a directory to store qc: mkdir qc 
Run quality control: 
fastqc -o qc/ Injected_R1.fastq.gz 
fastqc -o qc/ Injected_R2.fastq.gz 
Figure 7.4. Correlation of ESR1 with the old and new CCDC170 primers (CCDC170 and CCDC170(2-
3) respectively) in E2. 
Correlation in PX459-6 with E2 (A,B) and in DSB10 with E2 (C,D). R represents the spearman co-efficient 




Step 3: Trimming adapter content for q30 and above and discards anything outside the 
Illumina sequence 
Make a directory called trimmed: mkdir trimmed 
cutadapt -B file:IllAdapter.fasta -q 30 -b file:IllAdapter.fasta -O 5 --discard -o 
trimmed/Injected_trimmed_R1.fastq -p trimmed/Injected_trimmed_R2.fastq 
Injected_R1.fastq.gz Injected_R2.fastq.gz 
Step 4: Demultiplexing based on my primers to keep only sequences between them 
Make a directory called demux: mkdir demux 
cutadapt -e 0 --no-indels -g file:Primer.fasta -G file:Primer.fasta -o 
demux/Injected_demux__R1.fastq.gz -p demux/Injected_demux__R2.fastq.gz 
trimmed/Injected_trimmed_R1.fastq trimmed/Injected_trimmed_R2.fastq 
Step 5: Merge the paired end reads  
Make a directory called mergedPE: mkdir mergedPE 
flash -t 1 -O demux/Injected_demux__R1.fastq.gz demux/Injected_demux__R2.fastq.gz 
-o merged -d mergedPE 
Step 6: index the reference sequence  
Make a directory called ref: mkdir ref 
Move the ref.fasta file into the mkdir ref: cp ref.fasta ref/ 
index the reference: bwa index ref/RefSeq.fasta 
Step 7: Create the alignment  
Make a directory to store the alignment: mkdir aln 
bwa mem -t 1 ref/refseq.fasta mergedPE/merged.extendedFrags.fastq | samtools view -
bS - > aln/Injected_aln.bam 





samtools sort -o aln/Injected_aln aln/Injected_aln_sorted.bam 
samtools index Injected_aln_sorted.bam 
Step 9: Stack the alignment  
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